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ABSTRACT

This invention relates to processes and reagents for making
diaryliodonium salts, which are useful for the preparation of
fluorinated and radiofluorinated aromatic compounds.
28 Claims, No Drawings
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2
clo2.2.2]octane)bis(tetrafluoroborate)
(SelectFluorTM),
(1-fluoro-4-methyl-1,4-diazoniabicyclo[2.2.2]octane)bis
(tetrafluoroborate) (SelectFluor IITM), or optionally substi
tuted N-fluoropyridinium tetrafluoroborate;

PROCESSES AND REAGENTS FOR MAKING
DARYLODONUMISALTS
CROSS-REFERENCE TO RELATED
APPLICATIONS

wherein:

each X is, independently, a ligand that is a conjugate base
of an acid HX, wherein HX has a pKa of less than or equal to

This application claims priority to U.S. Provisional Appli
cation No. 61/655,860, filed Jun. 5, 2012, which is incorpo
rated by reference in its entirety.

12; and

Ar" is optionally substituted arylor heteroaryl, wherein Ar"
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TECHNICAL FIELD

This invention relates to processes and reagents for making
diaryliodonium salts, which are useful for the preparation of
fluorinated and radiofluorinated aromatic compounds.

does not have unprotected protic groups.
The present application further provides a process of con
Verting the compound of Formula Ito a compound of Formula
III:

15

III

xe
o
A11 NA2

BACKGROUND

Diaryliodonium salts are useful as arylating agents for a
large variety of organic and inorganic nucleophiles. They
have also been applied in metal-catalyzed cross-coupling
reactions (Ryan, J. H. and P.J. Stang, Tetrahedron Lett. 1997,
38, 5061-5064; Zhang, B.-X., et al., Heterocycles 2004, 64,
199-206: Kang, S.-K., et al., J. Org. Chem. 1996, 61, 4720
4724; Al-Qahtani, M. H. and V.W. Pike, Perkin 12000, 1033
1036; Kang, S.-K., et al., Tetrahedron Lett. 1997, 38, 1947
1950) due to the excellent leaving-group ability of the aryl
iodide moiety (Okuyama, T., et al., J. Am. Chem. Soc. 1995,
117, 3360-7). Other than these applications, diaryliodonium
salts were found to play a role as oxidants for dearomatization
of phenols (Moriarty, R. M. and O. Prakash, Org. React. (N.
Y.) 2001, 57, 327–415: Moore, J. D. and P. R. Hanson,
Chemtracts 2002, 15,74-80; Ciufolini, M.A., et al., Synthesis
2007, 3759-3772) and as cationic photoinitiators in photo
chemistry (Toba, Y., J. Photopolym. Sci. Technol. 2003, 16,
115-118: Crivello, J. V., J. Polym. Sci., Part A: Polym. Chem.
2009, 47, 866-875: Crivello, J. V., Polym. Prepr. (Am. Chem.
Soc., Div. Polym. Chem.) 2006, 47, 208-209).
Diaryliodonium salts are also useful for the synthesis of

aryl fluorides, for example, in the preparation of F labeled

radiotracers. Aryl fluorides are structural moieties in natural
products as well as a number of therapeutically important
compounds, including pharmaceuticals and positron emis
sion tomography (PET) tracers. Diaryliodonium salts are par
ticularly useful for the nucleophilic fluorination of electron
rich arenes, a class of compounds that is inaccessible using
conventional nucleophilic fluorination methods.
For at least these reasons, there is a need to develop new
routes in diaryliodonium salts, particularly those having a
broad range of functional groups. This application addresses

wherein Aris an optionally substituted aryl or heteroaryl.
25

The compound of Formula I can be isolated and then used
to prepare the compound of Formula III or the two steps can
be carried out in an efficient one-pot synthesis.
This process allows the preparation of iodine (III) precur
sors of Formula I without the use of acidic conditions or the

30

35

40

use of reagents that must be prepared in acidic media as in
other synthetic procedures. Acidic conditions are not compat
ible with substrates featuring acid sensitive moieties or het
eroatoms that are prone to protonation or oxidation. Hence,
the current process allows the synthesis of a broad range of
diaryliodonium salts, which were previously inaccessible.
For example, the process has been shown to be applicable to
both electron-rich and electron-deficient arenes and is toler

ant of molecules featuring acid sensitive moieties and pro
tected L-amino acid groups. Further, this process is also more
economical in that less than 2 equivalents of the oxidation
agent may be utilized to achieve the oxidation, unlike other
processes which use a high excess of the oxidation agent.
The present application also provides certain new com
pounds of Formulas I, II, III, V, VI, or VII.
DETAILED DESCRIPTION

45

The present application provides, interalia, a process for
making a compound of Formula I:

50

-IX):

this need and others.
SUMMARY

comprising treating a compound of Formula II:

The present application provides, interalia, a process for
making a compound of Formula I:

- X:

55

60

II

with a tetravalent silicon moiety having at least one X group
bound to Si; and (1-chloromethyl-4-fluoro-1,4-diazoniabicy
clo2.2.2]octane)bis(tetrafluoroborate), (1-fluoro-4-methyl
1,4-diazoniabicyclo[2.2.2]octane)bis(tetrafluoroborate), or
optionally substituted N-fluoropyridinium tetrafluoroborate;
wherein:

each X is, independently, a ligand that is a conjugate base
of an acid HX, wherein HX has a pKa of less than or equal to

comprising treating a compound of Formula II:
Ar—I

Ar—I

II

with a tetravalent silicon moiety having at least one X group
bound to Si; and (1-chloromethyl-4-fluoro-1,4-diazoniabicy

12; and

65

Ar' is optionally substituted aryl or heteroaryl.
In some embodiments, Ar" does not have any iodo groups
(e.g., Ar"—I has only the single iodo group).

US 9.278,959 B2
3

In some embodiments, Ar' is optionally substituted aryl or
heteroaryl, wherein Ar" does not have unprotected protic
groups. As used herein, protic groups' means groups having
a hydrogen atom directly attached to an oxygen, nitrogen or
Sulfur atom (non-limiting examples of these groups include
alcohols, primary and secondary amines, carbamates, ureas,
amides, Sulfonic acids, thiols, hydrazines, hydrazides, and
semicarbazides).
As described above, the current process allows the synthe
sis of a broad range of diaryliodonium salts, including both

10

electron-rich and electron-deficient arenes and is tolerant of

molecules featuring acid sensitive moieties and protected
L-amino acid groups.
Without wishing to be bound by any theory, the process is
believed to operate by the process shown in the example
below. It is thought that the highly activated I(III) intermedi
ate aryl-IF+, formed from two-electron oxidation of an aryl
iodide by F-TEDA-BF, is sufficiently Lewis acidic to
remove a fluoride from BF to form the aryl-IF trifluo
roborane complex. Aryl-IF reacts subsequently with TMS-X
to give 1a and TMSF, while boron trifluoride is coordinated
by the free amine of reduced Selectfluor to form the Zwitte
rionic adduct, which is able to exchange fluoride with excess
TMS-X (e.g., TMSOAc). The aryl-IF compound undergoes
a fast ligand exchange process with X—. The premixed
TMSOAc therefore converted aryl-IF to corresponding Arl
(OAc) immediately upon formation of ArF.

15

25

4
bamyl, di(C. alkyl)carbamyl, carboxy, amino, Ce alky
lamino, di-C alkylamino, Calkylcarbonyl, Calkoxy
carbonyl, C. alkylcarbonyloxy, Ce alkylcarbonylamino,
Calkylsulfonylamino, aminosulfonyl, Calkylaminosul
fonyl, di(C. alkyl)aminosulfonyl, aminosulfonylamino,
C. alkylaminosulfonylamino, di(C. alkyl)aminosulfony
lamino, aminocarbonylamino, Ce alkylaminocarbony
lamino, and di(Calkyl)aminocarbonylamino; wherein said
C- alkyl, Cao cycloalkyl-Ca-alkyl, Co heterocy
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co
aryl-C-alkyl, Co heteroaryl are each optionally substi
tuted by one or more groups selected from halo, cyano, nitro,
C- alkyl, Ce haloalkyl, C2-alkenyl, C2-alkynyl, C
alkoxy, hydroxy, Calkoxy, Chaloalkoxy, Calkylthio.
C. alkylsulfinyl, Ce alkylsulfonyl, carbamyl, C. alkyl
carbamyl, di(Calkyl)carbamyl, carboxy, amino, Calky
lamino, di-C alkylamino, Calkylcarbonyl, Calkoxy
carbonyl, C. alkylcarbonyloxy, Ce alkylcarbonylamino,
Calkylsulfonylamino, aminosulfonyl, Calkylaminosul
fonyl, di(C. alkyl)aminosulfonyl, aminosulfonylamino,
C. alkylaminosulfonylamino, di(C. alkyl)aminosulfony
lamino, aminocarbonylamino, C alkylaminocarbony
lamino, di(C. alkyl)aminocarbonylamino, and Co
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co
heteroaryl.
C
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In some embodiments, the process is carried out in the
absence of added acid (e.g., protic acid).
In some embodiments, the process utilizes (1-chlorom
ethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane)bis(tet
rafluoroborate).
In some embodiments, the process utilizes (1-fluoro-4methyl-1,4-diazoniabicyclo[2.2.2]octane)bis(tetrafluorobo
rate).
In some embodiments, the process utilizes N-fluoropyri
dinium tetrafluoroborate, wherein the pyridine ring is option
ally substituted by 1, 2, 3, 4, or 5 groups independently
selected from halo, cyano, nitro, Ce alkyl, Ce haloalkyl,
Coalkenyl, C2-alkynyl, Co cycloalkyl, Co cycloalkyl
C-alkyl, Co heterocycloalkyl, Co heterocycloalkyl
C-alkyl, Cao aryl, Co aryl-Ca-alkyl, Coheteroaryl,
hydroxy, C. alkoxy, C- haloalkoxy, Co alkylthio. C
alkylsulfinyl, Ce alkylsulfonyl, carbamyl, Ce alkylcar

50

55

60

OMe

In some embodiments, the process utilizes N-fluoropyri
dinium tetrafluoroborate, wherein the pyridine ring is option
ally substituted by 1, 2, 3, 4, or 5 groups independently
selected halo groups.
In some embodiments, the process utilizes N-fluoropyri
dinium tetrafluoroborate, wherein the pyridine ring is option
ally substituted by 1, 2, 3, 4, or 5 groups independently
selected halo groups.
In some embodiments, the process utilizes N-fluoro-2,3,4,
5,6-pentachloropyridinium tetrafluoroborate.
In some embodiments, the process utilizes less than 2
equivalents of (1-chloromethyl-4-fluoro-1,4-diazoniabicyclo
2.2.2]octane)bis(tetrafluoroborate), (1-fluoro-4-methyl-1,4diazoniabicyclo[2.2.2]octane)bis(tetrafluoroborate),

65

O

optionally substituted N-fluoropyridinium tetrafluoroborate
for 1 equivalent of the compound of Formula II. In some
embodiments, the process utilizes less than 1.5 equivalents of

US 9.278,959 B2
5
(1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane)
bis(tetrafluoroborate), (1-fluoro-4-methyl-1,4-diazoniabicy
clo2.2.2]octane)bis(tetrafluoroborate), or optionally substi
tuted N-fluoropyridinium tetrafluoroborate for 1 equivalent
of the compound of Formula II.
In some embodiments, each X is, independently, a ligand
that is a conjugate base of an acid HX, wherein HX has a pKa
of less than or equal to 5.
In some embodiments, X can be chosen from halide, aryl
carboxylate, alkyl carboxylate, phosphate, phosphonate,
phosphonite, azide, thiocyanate, cyanate, phenoxide, triflate,

6
Some embodiments, the process utilizes 2.5 equivalents to 3
equivalents of the tetravalent silicon moiety for 1 equivalent
of the compound of Formula II. In some embodiments, the

process utilizes 2 equivalents or more of (R'),Si X for 1

equivalent of the compound of Formula II. In some embodi
ments, the process utilizes 2.5 equivalents to 3 equivalents of

(R')Si X for 1 equivalent of the compound of Formula II.

10

thiolates, and stabilized enolates.

In some embodiments, X is O(C=O)CH.
In some embodiments, the tetravalent silicon moiety is

(R'),Si X, (R').Si (X), R'Si (X), and Si(X):
wherein each R' is, independently, C, alkyl or aryl.
In some embodiments, the tetravalent silicon moiety is
(R'),Si X, wherein each R' is, independently, C-12 alkylor
aryl.
In some embodiments, each R' is, independently, C-12
alkyl.
In some embodiments, each R' is, independently, Ca
alkyl.
In some embodiments, each R' is independently, methyl.
In some embodiments, (R'),Si X is (CH),Si X.
In some embodiments, (R')Si X is (CH)Si-O
(C=O)CH.
At various points, the process utilizes protecting groups.
Appropriate protecting groups for various functional groups
include, but are not limited to the protecting groups delin
eated in Wuts and Greene, Protective Groups in Organic
Synthesis, 4th ed., John Wiley & Sons: New Jersey, which is
incorporated herein by reference in its entirety. For example,
protecting groups for amines include, but are not limited to,
t-butoxycarbonyl (BOC), benzyloxycarbonyl (Cbz), 2.2.2trichloroethoxycarbonyl (Troc), 2-(4-trifluoromethylphenyl
Sulfonyl)ethoxycarbonyl (Tsc), 1-adamantyloxycarbonyl
(Adoc), 2-adamantylcarbonyl (2-Adoc), 2,4-dimethylpent-3yloxycarbonyl (Doc), cyclohexyloxycarbonyl (Hoc), 1,1dimethyl-2.2.2-trichloroethoxycarbonyl (TcPOC), vinyl,
2-chloroethyl 2-phenylsulfonylethyl, allyl, benzyl, 2-ni
trobenzyl, 4-nitrobenzyl, diphenyl-4-pyridylmethyl, N',N'dimethylhydrazinyl, methoxymethyl, t-butoxymethyl
(Bum), benzyloxymethyl (BOM), or 2-tetrahydropyranyl
(THP).
Carboxylic acids can be protected as their alkyl, allyl, or
benzyl esters, among other groups.
Alcohols can be protected as esters, such as acetyl, ben
Zoyl, or pivaloyl, or as ethers. Examples of ether protecting
groups for alcohols include, but are not limited to alkyl, allyl,
benzyl, methoxymethyl (MOM), t-butoxymethyl, tetrahy
dropyranyl (THP), p-methoxybenzyle (PMB), trity1, and
methoxyethoxymethyl (MEM).
In some embodiments, the protecting groups are acid labile
protecting groups.
In some embodiments, the protecting groups are base labile
protecting groups.
In some embodiments, the protecting group are acid labile
protecting groups, which can be easily be removed at the end
of all synthetic steps under acidic deprotection conditions.
In Some embodiments, the process utilizes 2 equivalents or
more of the tetravalent silicon moiety for 1 equivalent of the
compound of Formula II. As used herein, the equivalents are
per X group bound to the Siatom of the tetravalent silicon
moiety (e.g., when 2X groups are bound to the Siatom, then
only 1 equivalent or more of the tetravalent silicon moiety are
needed for 1 equivalent of the compound of Formula II). In

15

In some embodiments, the processes comprises treating a
compound of Formula II with (CH),Si O(C=O)CH; and
(1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane)
bis(tetrafluoroborate). In some embodiments, the processes
comprises treating a compound of Formula II with 2.5 equiva
lents to 3 equivalents of (CH)-Si-O(C=O)CH; and less
than 1.5 equivalents of (1-chloromethyl-4-fluoro-1,4-diazo
niabicyclo[2.2.2]octane)bis(tetrafluoroborate).
In some embodiments:

Ar' is aryl or heteroaryl, which is optionally substituted by
one or more groups independently selected from halo, cyano,
nitro, C-alkyl, Chaloalkyl, C2-alkenyl, C2-alkynyl,
C- alkoxy, C-14 cycloalkyl, C-14 cycloalkyl-Ca-alkyl,
C. heterocycloalkyl, C. heterocycloalkyl-C-alkyl,
Co-14 aryl, C-14 aryl-C-4-alkyl, C-14 heteroaryl, C-14 het
eroaryl-C-alkyl, - S(=O)R. S(=O).R", S(=O).

25

30

35

40
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NRSR, C(=O)R, C(=O)NR'R'', OC(=O)R",
OC(=O)NR'R'', NRC(=O)R", NR“C(=O)CR,
NRC(=O)NRSNR, NRS(—O).R., NR“S(—O),
NRSR, C( NR)NRSR, NRC( NR)NRSR, OC,
–SR, S(=O),OR, C(=O)CR', and NR&R";

wherein said C. alkyl, Ce haloalkyl, C2-alkenyl, C2
alkynyl, Calkoxy, C-acycloalkyl, C-acycloalkyl-Ca
alkyl, C. heterocycloalkyl, C. heterocycloalkyl-Ca
alkyl, Caryl, Caryl-C-alkyl, C. heteroaryl, and
C. heteroaryl-C-alkyl are each optionally substituted by

one or more independently selected R groups;
each R is independently selected from H. C. alkyl, CN,

Calkoxy, or C(O)C alkyl;
each R" is independently selected from H. C. alkyl, C.
haloalkyl, C2-alkenyl, C2-alkynyl, aryl, Cao cycloalkyl,
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co
heterocycloalkyl-Ca-alkyl, Co aryl, Co aryl-C-alkyl,
Coheteroaryl, wherein said C. alkyl, Chaloalkyl, C
alkenyl, C- alkynyl, Co cycloalkyl, Co cycloalkyl
C-alkyl, Co heterocycloalkyl, Co heterocycloalkyl
Ca-alkyl, Cao aryl, Co aryl-Ca-alkyl, Coheteroaryl,
and Co. heteroaryl-C-alkyl are each optionally Substi

tuted by one or more independently selected R groups;
each R is independently selected from C, alkyl, C.

50

55

haloalkyl, C2-alkenyl, C2-alkynyl, Cso cycloalkyl, Cso
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co
heteroaryl, wherein said C. alkyl, Chaloalkyl, C2-alk
enyl, C2-alkynyl, aryl, Cao cycloalkyl, Cso cycloalkyl
C-alkyl, Co heterocycloalkyl, Co heterocycloalkyl
C-alkyl, Co aryl, Co aryl-C-alkyl, Coheteroaryl,
and Co. heteroaryl-C-alkyl are each optionally Substi

tuted by one or more independently selected R groups:
60

65

each R is independently selected from a protecting group,
C- alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co
aryl-C-alkyl, Co heteroaryl, wherein said C. alkyl,
C- haloalkyl, C2- alkenyl, C2- alkynyl, aryl, Cso
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca
alkyl are each optionally Substituted by one or more indepen

dently selected R groups;

US 9.278,959 B2
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7

each R" is independently selected from a protecting group,

C. alkyl, Ce haloalkyl, Calkenyl, Ce alkynyl, Co
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl,
C. haloalkyl, C2- alkenyl, C- alkynyl, aryl, Cso
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o
aryl-C-alkyl, Co heteroaryl, and Coheteroaryl-Calkyl are each optionally Substituted by one or more indepen

OC(=O)R', OC(=O)NR3'R'', NRC(=O)R',
NRC(O)OR, NRC(O)NR&NR'', NR'S
(—O).R', NR'S(=O)NR's 'R'', C(-NR)NR'R'',
NRC(—NR)NR&R'', OR', SR', S(–O).OR',
—C(=O)CR', and - NR3'R'': wherein said C. alkyl,

10

dently selected R groups;
each R' is independently selected from H. C. alkyl, C.

dently selected R groups;

each R is independently selected from a protecting group,
C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o
aryl-C-alkyl, Co heteroaryl, wherein said C. alkyl,
C. haloalkyl, C2- alkenyl, C- alkynyl, aryl, Cso
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca
alkyl are each optionally Substituted by one or more indepen

15

each R' is independently selected from C, alkyl, C

25

30

each R', R and R' is independently selected from a pro

dently selected R groups;
or alternatively, RandR', taken together with the atoms to

35

40

each R" is independently selected from a protecting

45

R groups;
or alternatively, RandR, taken together with the atoms to

50

R groups;

55

R groups;

or alternatively, RandR', taken together with the nitrogen

atom to which they are attached, form a heterocycloalkyl or
heteroaryl ring, which is optionally substituted by one or

more R groups;
each R is independently selected from halo, cyano, nitro,

C. alkyl, C- haloalkyl, C- haloalkyl, C2-alkenyl, C2
alkynyl, Calkoxy, Co cycloalkyl, Co cycloalkyl-Calkyl, Co heterocycloalkyl, C7-o heterocycloalkyl-Calkyl, Co-o aryl, Co-o aryl-C-4-alkyl, Coheteroaryl, C-10

heteroaryl-C-alkyl,

S(=O)NR3'R'',

S(=O)R',
S(=O).R',
C(=O)R'', C(=O)NR'R'',

group, Co alkyl, Chaloalkyl, C2-alkenyl, C2-alkynyl,
Cao cycloalkyl, Cao cycloalkyl-Ca-alkyl, Coheterocy
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co
aryl-C-alkyl, Co heteroaryl, wherein said C. alkyl,
C- haloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl,
Co cycloalkyl-C-alkyl, Co heterocycloalkyl, Co
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl,
Co heteroaryl, and Co. heteroaryl-C-alkyl are each
optionally substituted by one or more independently selected

Rgroups;
each R' is independently selected from a protecting group,

or alternatively, RandR, taken together with the atoms to

which they are attached, form a heterocycloalkyl or het
eroaryl ring, which is optionally substituted by one or more

C. alkyl, Ce haloalkyl, Calkenyl, Ce alkynyl, Co
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl,
C- haloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl,
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl,
Co heteroaryl, and Co heteroaryl-C-alkyl are each
optionally substituted by one or more independently selected

R groups;

which they are attached, form a heterocycloalkyl or het
eroaryl ring, which is optionally substituted by one or more
which they are attached, form a heterocycloalkyl or het
eroaryl ring, which is optionally substituted by one or more

haloalkyl, Calkenyl, C2-alkynyl, Co cycloalkyl, Co
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co
heteroaryl, wherein said C. alkyl, Chaloalkyl, C2-alk
enyl, C2-alkynyl, Cao cycloalkyl, Cao cycloalkyl-Ca
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-Ca
alkyl, Cao aryl, Cao aryl-Ca-alkyl, Co heteroaryl, and
Coheteroaryl-C-alkyl are each optionally substituted by

one or more independently selected R groups;
each R' is independently selected from a protecting group,

dently selected R groups;

tecting group, Ce alkyl, Ce haloalkyl, Calkenyl, C
alkynyl, Co cycloalkyl, Cao cycloalkyl-Ca-alkyl, Co
heterocycloalkyl, Co heterocycloalkyl-C-alkyl, Co
aryl, Co-oaryl-Ca-alkyl, Coheteroaryl, wherein said C
alkyl, Chaloalkyl, C2-alkenyl, C2-alkynyl, aryl, Cso
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o
aryl-C-alkyl, Co heteroaryl, and Coheteroaryl-Calkyl are each optionally Substituted by one or more indepen

haloalkyl, C2-alkenyl, C2-alkynyl, Cso cycloalkyl, Cso
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co
heteroaryl, wherein said C. alkyl, Chaloalkyl, Calk
enyl, C2-alkynyl, Cao cycloalkyl, Cao cycloalkyl-Ca
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-Ca
alkyl, Cao aryl, Cao aryl-Ca-alkyl, Co heteroaryl, and
Coheteroaryl-C-alkyl are each optionally Substituted by

one or more independently selected R groups;

dently selected R groups;
each R is independently selected from a protecting group,

C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl,
C. haloalkyl, C- alkenyl, C- alkynyl, aryl, Co
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca
alkyl are each optionally substituted by one or more indepen

Chaloalkyl, C2-alkenyl, C2-alkynyl, Co alkoxy, Cao
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co
aryl-C-alkyl, Co heteroaryl, and Coheteroaryl-Ca
alkyl are each optionally Substituted by one or more indepen

60
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C- alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl,
C- haloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl,
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co
heterocycloalkyl-Ca-alkyl, Co aryl, Co aryl-C-alkyl,
Co heteroaryl, and Co. heteroaryl-C-alkyl are each
optionally substituted by one or more independently selected

Rgroups;
each R is independently selected from a protecting group,

C- alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy

US 9.278,959 B2
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cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o
aryl-C-alkyl, Co heteroaryl, wherein said C. alkyl,
Chaloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl,
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl,
Co heteroaryl, and Co. heteroaryl-C-alkyl are each
optionally substituted by one or more independently selected

10
heteroaryl, wherein said C. alkyl, Chaloalkyl, C2-alk
enyl, C- alkynyl, Co cycloalkyl, Co cycloalkyl-Ca
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-Ca
alkyl, Cao aryl, Cao aryl-Ca-alkyl, Co heteroaryl, and
Coheteroaryl-C-alkyl are each optionally substituted by

one or more independently selected R'groups;
each R is independently selected from a protecting group,

Rgroups;
each R', R3 and R' is independently selected from a

protecting group, C-alkyl, Chaloalkyl, C2-alkenyl, C2
alkynyl, Co cycloalkyl, Cao cycloalkyl-Ca-alkyl, Co
heterocycloalkyl, Co heterocycloalkyl-C-alkyl, Co
aryl, Co-oaryl-Ca-alkyl, Coheteroaryl, wherein said C
alkyl, Ce haloalkyl, C- alkenyl, C- alkynyl, Co
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca
alkyl are each optionally Substituted by one or more indepen

10

15

R" groups:

each R is independently selected from a protecting

dently selected R groups;

or alternatively, R'' and R', taken together with the atoms

to which they are attached, form a heterocycloalkyl or het
eroaryl ring, which is optionally substituted by one or more

R groups;

or alternatively, R'' and R', taken together with the atoms

to which they are attached, form a heterocycloalkyl or het
eroaryl ring, which is optionally substituted by one or more

25

Rgroups;
or alternatively, R'' and R', taken together with the atoms

to which they are attached, form a heterocycloalkyl or het
eroaryl ring, which is optionally substituted by one or more

Rgroups;
or alternatively, R'' and R', taken together with the nitro

30

gen atom to which they are attached, form a heterocycloalkyl
or heteroaryl ring, which is optionally substituted by one or

more R groups;
each R is independently selected from halo, cyano, nitro,

C. alkyl, C- haloalkyl, C- haloalkyl, C2-alkenyl, C2
alkynyl, Calkoxy, Cao cycloalkyl, Co cycloalkyl-Ca
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-Calkyl, Cao aryl, Cao aryl-Ca-alkyl, Coheteroaryl, Co

heteroaryl-C-alkyl,

S(=O)R’,

35

40

S(=O)R’,

S(=O)NR8R, C(=O)R’?, C(=O)NR8R,
OC(=O)R’, OC(=O)NR&R', NR°C(=O)R’,
NRC(O)OR, NRC(O)NR3°NR, NRS
(—O).R.?, NR'2S(O)NR3°R2, C( NR)NR3°Rh2,
NRC( NR)NR8R, OR, SR', S(O).OR,
—C(=O)CR?, and - NRSR’; wherein said C. alkyl,

Chaloalkyl, C2-alkenyl, C2-alkynyl, Calkoxy, Cao
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca
alkyl are each optionally Substituted by one or more indepen

45
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R" groups:
each R’ is independently selected from a protecting group,

C-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Cso
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl,
Chaloalkyl, Calkenyl, C. alkynyl, Co cycloalkyl,
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl,
Co heteroaryl, and Co heteroaryl-C-alkyl are each
optionally substituted by one or more independently selected

R“groups:
each R is independently selected from a protecting group,

C- alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl,
Chaloalkyl, Calkenyl, C. alkynyl, Co cycloalkyl,
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co
heterocycloalkyl-Ca-alkyl, Co aryl, Co aryl-C,e-alkyl,
Co heteroaryl, and Co. heteroaryl-C-alkyl are each
optionally substituted by one or more independently selected

each R', R and R' is independently selected from a

55

60

protecting group, Calkyl, Chaloalkyl, Calkenyl, C
alkynyl, Co cycloalkyl, Cao cycloalkyl-Ca-alkyl, Co
heterocycloalkyl, Co heterocycloalkyl-C-alkyl, Co
aryl, Cao aryl-C-alkyl, Coheteroaryl, wherein said C.
alkyl, Ce haloalkyl, C2- alkenyl, C2-alkynyl, Cso
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co
aryl-C-alkyl, Co heteroaryl, and Coheteroaryl-Ca
alkyl are each optionally Substituted by one or more indepen

dently selected R groups;

one or more independently selected R' groups;

each R’ is independently selected from C, alkyl, C.

haloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl, Cso
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co

group, Co alkyl, Chaloalkyl, C2-alkenyl, C2-alkynyl,
Co cycloalkyl, Co cycloalkyl-C-alkyl, Coheterocy
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl,
Chaloalkyl, Calkenyl, C. alkynyl, Co cycloalkyl,
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co
heterocycloalkyl-Ca-alkyl, Co aryl, Co aryl-C-alkyl,
Co heteroaryl, and Co. heteroaryl-C-alkyl are each
optionally substituted by one or more independently selected

R" groups:

dently selected R' groups;
each R' is independently selected from H. C. alkyl, C.

haloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl, Cso
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co
heteroaryl, wherein said C. alkyl, Chaloalkyl, C2-alk
enyl, C2-alkynyl, Cao cycloalkyl, Cao cycloalkyl-Ca
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-Calkyl, Co aryl, Co aryl-C-alkyl, Coheteroaryl, and
Coheteroaryl-C-alkyl are each optionally Substituted by

C. alkyl, Ce haloalkyl, Calkenyl, Ce alkynyl, Co
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co
aryl-C-alkyl, Co heteroaryl, wherein said C. alkyl,
C- haloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl,
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co
heterocycloalkyl-Ca-alkyl, Co aryl, Co aryl-C-alkyl,
Co heteroaryl, and Co. heteroaryl-C-alkyl are each
optionally substituted by one or more independently selected

or alternatively, RandR', taken together with the atoms

65

to which they are attached, form a heterocycloalkyl or het
eroaryl ring, which is optionally substituted by one or more

R“groups:

US 9.278,959 B2
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to which they are attached, form a heterocycloalkyl or het
eroaryl ring, which is optionally substituted by one or more

12
New Jersey, which is incorporated herein by reference in its
entirety. For example, amine groups can be protected by
reacting di-tert-butyl dicarbonate (BOC anhydride in the
presence of a tertiary amine (e.g., 4-dimethylpyridine and
triethylamine) to form a BOC (tert-butylcarbonyl) protected

to which they are attached, form a heterocycloalkyl or het
eroaryl ring, which is optionally substituted by one or more

amine

or alternatively, RandR', taken together with the atoms

R“groups:
or alternatively, RandR, taken together with the atoms

In some embodiments, the present application provides a
process of converting the compound of Formula I to a com
pound of Formula III:

R“groups:
or alternatively, RandR', taken together with the nitro

gen atom to which they are attached, form a heterocycloalkyl
or heteroaryl ring, which is optionally substituted by one or

10

more R groups;
each R is independently selected from halo, cyano, nitro,
C, alkyl, Chaloalkyl, Ce alkyl-NR'—C, alkylene,

Coalkyl-O-C-alkylene, C2-alkenyl, C2-alkynyl, Cso
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o
aryl-Ca-alkyl, Coheteroaryl, Coheteroaryl-Ca-alkyl,
hydroxy, C. alkoxy, C- haloalkoxy, Co alkylthio. C
alkylsulfinyl, Ce alkylsulfonyl, carbamyl, Ce alkylcar
bamyl, di(C. alkyl)carbamyl, carboxy, amino, C alky
lamino, di-C alkylamino, Ce alkylcarbonyl, Calkoxy
carbonyl, C. alkylcarbonyloxy, C alkylcarbonylamino,
Calkylsulfonylamino, aminosulfonyl, Calkylaminosul
fonyl, di(C. alkyl)aminosulfonyl, aminosulfonylamino,
C. alkylaminosulfonylamino, di(C. alkyl)aminosulfony
lamino, aminocarbonylamino, Ce alkylaminocarbony
lamino, and di(Calkyl)aminocarbonylamino; wherein said
C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, C
alkoxy, alkylene, C alkyl-O-C alkylene, Co
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co
aryl-C-alkyl, Co heteroaryl, and Coheteroaryl-Calkyl are each optionally Substituted by one or more groups
selected from halo, cyano, nitro, C alkyl, Chaloalkyl,
C2-alkenyl, C2-alkynyl, C-calkoxy, hydroxy, Calkoxy,
Chaloalkoxy, Calkylthio, Calkylsulfinyl, Ce alkyl
Sulfonyl, carbamyl, Ce alkylcarbamyl, di(C. alkyl)car
bamyl, carboxy, amino, Calkylamino, di-C alkylamino,
C. alkylcarbonyl, Calkoxycarbonyl, C. alkylcarbony
loxy, Ce alkylcarbonylamino, Ce alkylsulfonylamino,
aminosulfonyl, C. alkylaminosulfonyl, di(C. alkyl)ami
nosulfonyl, aminosulfonylamino, Ce alkylaminosulfony
lamino, di(C. alkyl)aminosulfonylamino, aminocarbony
lamino,
C1-6
alkylaminocarbonylamino,
alkyl)
aminocarbonylamino, Cao cycloalkyl, Cso cycloalkyl
C -alkyl, Co heterocycloalkyl, Co heterocycloalkyl
C-4-alkyl, Co-lo aryl, Co-o C1-10 heteroaryl and Co het
eroaryl-C alkyl; and

each R" is independently selected from Hand C, alkyl.

III

15

wherein Ari is an optionally substituted aryl or heteroaryl.
In some embodiments, the conversion of the compound of
Formula I to a compound of Formula III is done in the same
pot as the reaction of the compound of Formula II to form the
compound of Formula I.
In some embodiments, the converting comprises reacting
the compound of Formula I with a compound of Formula IV:
25

wherein M' is aborate, stannane, silane, or zinc moiety.
In some embodiments, M' is Sn(R), Si(R), B(OR), or
BCX),M; wherein:

30

35

M° is a counterion.

40

In some embodiments, the Zinc moiety is an Zinc halide
(Zn-halo). In some embodiments, the arylzinc halide is Zinc
chloride.

In some embodiments, the compound of Formula IV is

45

ArBF.M.
In some embodiments, the compound of Formula IV is
Ar’BFK.

In some embodiments, the process is carried out in the
presence of a catalyst.
In some embodiments, the catalyst is trimethylsilyl trifluo

50 rOacetate.

The use of ArBFM is preferred over the other reagents.

is provided that each hydrogen atom in which is directly
attached to a nitrogen atom, Sulfur atom, or oxygen atom in
any of the aforementioned groups (e.g., heteroaryl, heterocy

cloalkyl, C. alkyl-NR" C- alkylene, hydroxy, car

each R is, independently, C alkyl:
each R' is, independently, Ce alkyl,
each R is, independently, OH or Calkoxy; or
two R groups, taken together with the oxygen atoms to
which they are attached and the boron atom to which the
oxygen atoms are attached, form a 5- to 6-membered hetero
cyclic ring, which is optionally Substituted with 1, 2, 3, or 4
C. alkyl groups;

each X is, independently, halo; and

In one embodiments of the aformentioned embodiment, it

bamyl, carboxy, amino, C alkylamino, Calkylsulfony
lamino, aminosulfonyl, C.
alkylaminosulfonyl,
aminosulfonylamino, Calkylaminosulfonylamino, di(C.
alkyl)aminosulfonylamino, aminocarbonylamino, Calky
laminocarbonylamino, and di(C. alkyl)aminocarbony
lamino) is replaced by a protecting group.
Starting materials of Formula II can be obtained by react
ing the aryl or heteroaryl substrate with a N-iodosuccinamide
(NIS) in an appropriate solvent such as dry acetonitrile to give
a compound of Formula II. Protecting groups can added if
necessary as described in Wuts and Greene, Protective
Groups in Organic Synthesis, 4th ed., John Wiley & Sons:

xe
o
A11 NA2

55
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Compared to organostannanes, organoboranes are relatively
straightforward to handle and are quite reactive toward I(III)
compounds. However, organoboranes themselves are limited
by the inherent characteristics of the in situ hydroboration
reaction used to create them. They also suffer from high
sensitivity to air and poor functional-group compatibility in
Some cases. In contrast, aryltrifluoroborates are stable, crys
talline compounds that have been shown to overcome these
limitations. Organotrifluoroborates can be easily prepared
from inexpensive materials. They are stable to air and mois
ture, features that allow shipping and storage of these
reagents for long periods of time without noticeable degra
dation. Their versatility and stability has made them excellent
reagents in many organic reactions. Further, trifluoroborates
have the ability to resist chemical oxidation. This feature
offers aryltrifluoroborates a unique opportunity to preserve

US 9.278,959 B2
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haloalkyl, C2-alkenyl, C2-alkynyl, aryl, Cao cycloalkyl,
Co cycloalkyl-C-alkyl, Co heterocycloalkyl, Co
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl,
Co heteroaryl, and Co. heteroaryl-C-alkyl are each
optionally substituted by one or more independently selected

13
the carbon-boron bond during the oxidation of remote func
tionality within the same molecule. Organoboron compounds
are generally incompatible with oxidants, which readily
cleave the labile carbon-boron bond. Organotrifluoroborates
can be utilized to overcome this limitation in an important
way; since the organometallic reagent needs to be stable to
excess Selectfluor reagent that is present in one-pot synthetic
approach. The oxidative strength of Selectfluor reagent is
well tolerated by aryltrifluoroborates; they are unffected by
residual Selectfluor.

R groups;

10

In one embodiment (a), Ar' and Ari are each, indepen

dently, aryl or heteroaryl, which is optionally substituted by
one or more groups independently selected from halo, cyano,
nitro, Calkyl, Chaloalkyl, Calkenyl, C2-alkynyl,
C. alkoxy, C-14 cycloalkyl, C-14 cycloalkyl-Ca-alkyl,
C. heterocycloalkyl, C. heterocycloalkyl-C-alkyl,
Co-14 aryl, C-14 aryl-C-4-alkyl, C-14 heteroaryl, C-14 het
eroaryl-C-alkyl, —S(=O)R’, S(=O).R. S(=O)

15

dently selected R groups;
each R is independently selected from a protecting group,

NRSR, C(=O)NRSR, OC(=O)R, OC(=O)
NR&R", NR“C(=O)R", NRC(=O)CR, NR“C
(=O)NRSNR, NRS(—O).R, NRS(=O)NRSR,
C(-NR)NR'R'', NR“C(—NR)NR'R'', OC, SR,
—S(=O)OR, C(=O)CR, and NRSR'; wherein said

C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, C
alkoxy, C-14 cycloalkyl, C-14 cycloalkyl-Ca-alkyl, C-14
heterocycloalkyl, C-a heterocycloalkyl-C-alkyl, C
aryl, C-14 aryl-Ca-alkyl, C-14 heteroaryl, and C-14 het
eroaryl-C-alkyl are each optionally substituted by one or

25

each R', R and R' is independently selected from a pro

30

35

40

tuted by one or more independently selected R groups;
each R is independently selected from C, alkyl, C.

haloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl, Cso
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co
heteroaryl, wherein said C. alkyl, Chaloalkyl, C2-alk
enyl, C- alkynyl, aryl, Co cycloalkyl, Co cycloalkyl
C-alkyl, Co heterocycloalkyl, Co heterocycloalkyl
C-alkyl, Co aryl, Co aryl-C-alkyl, Coheteroaryl,
and Co. heteroaryl-C-alkyl are each optionally Substi

dently selected R groups;
or alternatively, RandR', taken together with the atoms to

R groups;
or alternatively, RandR', taken together with the atoms to

45

which they are attached, form a heterocycloalkyl or het
eroaryl ring, which is optionally substituted by one or more

R groups;

or alternatively, RandR, taken together with the atoms to

50

which they are attached, form a heterocycloalkyl or het
eroaryl ring, which is optionally substituted by one or more

R groups;
or alternatively, RandR', taken together with the nitrogen

atom to which they are attached, form a heterocycloalkyl or
heteroaryl ring, which is optionally substituted by one or
55

60

dently selected R groups;
each R" is independently selected from a protecting group,

C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso
cycloalkyl, Co cycloalkyl-C-alkyl, heterocycloalkyl,
Coheterocycloalkyl-Ca-alkyl, Co-o aryl, Co-oaryl-Ca
alkyl, Co heteroaryl, wherein said C. alkyl, C.

tecting group, Ce alkyl, Ce haloalkyl, Calkenyl, C
alkynyl, Co cycloalkyl, Cao cycloalkyl-Ca-alkyl, Co
heterocycloalkyl, Co heterocycloalkyl-Ca-alkyl, Co
aryl, Co aryl-C-alkyl, Coheteroaryl, wherein said C.
alkyl, Chaloalkyl, C2-alkenyl, C2-alkynyl, aryl, Cso
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca
alkyl are each optionally Substituted by one or more indepen
which they are attached, form a heterocycloalkyl or het
eroaryl ring, which is optionally substituted by one or more

tuted by one or more independently selected R groups;

each R is independently selected from a protecting group,
C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o
aryl-C-alkyl, Co heteroaryl, wherein said C. alkyl,
C. haloalkyl, C2- alkenyl, C- alkynyl, aryl, Cso
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca
alkyl are each optionally Substituted by one or more indepen

C- alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl,
C. haloalkyl, C- alkenyl, C- alkynyl, aryl, Co
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca
alkyl are each optionally Substituted by one or more indepen

dently selected R groups;

more independently selected R groups;

each R" is independently selected from H. C. alkyl, CN,
Calkoxy, or C(O)C alkyl;
each R" is independently selected from H. C. alkyl, C.
haloalkyl, Calkenyl, C-alkynyl, aryl, Co cycloalkyl,
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co
heterocycloalkyl-Ca-alkyl, Co aryl, Co aryl-C-alkyl,
Coheteroaryl, wherein said C. alkyl, Chaloalkyl, C
alkenyl, C2-alkynyl, Cso cycloalkyl, Cao cycloalkyl
C-alkyl, Co heterocycloalkyl, Co heterocycloalkyl
C-alkyl, Cao aryl, Co aryl-Ca-alkyl, Coheteroaryl,
and Co heteroaryl-C-alkyl are each optionally substi

each R is independently selected from a protecting group,
C- alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl,
C- haloalkyl, C2- alkenyl, C2- alkynyl, aryl, Cso
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca
alkyl are each optionally Substituted by one or more indepen

65

more R groups;
each R is independently selected from halo, cyano, nitro,

C- alkyl, Chaloalkyl, C- haloalkyl, C2-alkenyl, C2
alkynyl, Calkoxy, Cao cycloalkyl, Cao cycloalkyl-Ca
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-Ca
alkyl, Co-o aryl, Co-o aryl-C-4-alkyl, Coheteroaryl, C-10

heteroaryl-C-alkyl,
S(=O)R',
S(=O).R',
S(=O)NR3'R'', C(=O)R'', C(=O)NR'R'', OC
(=O)R'', OC(=O)NR&R'', NRS(=O)NR&R'',
C( NR)NR3'R'', NRC( NR)NR&R'',
OR,
SR', S(–O),OR', C(=O)CR?, and NR&R';

wherein said C. alkyl, Ce haloalkyl, C2-alkenyl, C2
alkynyl, Calkoxy, Cao cycloalkyl, Cao cycloalkyl-Ca
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alkyl, Co heterocycloalkyl, Co heterocycloalkyl-Calkyl, Co aryl, Co aryl-C-alkyl, Coheteroaryl, and
Coheteroaryl-C-alkyl are each optionally Substituted by

16
Co heteroaryl, and Co. heteroaryl-C-alkyl are each
optionally substituted by one or more independently selected

haloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl, Cso
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero
cycloalkyl-Ca-alkyl, Co aryl, Co aryl-C-alkyl, Co
heteroaryl, wherein said C. alkyl, Chaloalkyl, C2-alk
enyl, C2-alkynyl, Cao cycloalkyl, Cao cycloalkyl-Ca
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-Calkyl, Cao aryl, Co-o aryl-Ca-alkyl, Coheteroaryl, and
Coheteroaryl-C-alkyl are each optionally Substituted by

protecting group, Calkyl, Chaloalkyl, Calkenyl, C
alkynyl, Co cycloalkyl, Cao cycloalkyl-Ca-alkyl, Co
heterocycloalkyl, Co heterocycloalkyl-C-alkyl, Co
aryl, Co aryl-C-alkyl, Coheteroaryl, wherein said C.
alkyl, Ce haloalkyl, C2- alkenyl, C2-alkynyl, Cso
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca
alkyl are each optionally Substituted by one or more indepen

R groups;

one or more independently selected R groups;
each R' is independently selected from H. C. alkyl, C.

one or more independently selected R groups;

each R' is independently selected from C. alkyl, C

each R', R' and R' is independently selected from a

10

15

haloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl, Cso
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co
heteroaryl, wherein said C. alkyl, Chaloalkyl, C2-alk
enyl, C- alkynyl, Co cycloalkyl, Co cycloalkyl-Calkyl, Co heterocycloalkyl, Co heterocycloalkyl-Calkyl, Cao aryl, Co-o aryl-Ca-alkyl, Coheteroaryl, and
Coheteroaryl-C-alkyl are each optionally substituted by

one or more independently selected R groups;
each R' is independently selected from a protecting group,

C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl,
Chaloalkyl, C2-alkenyl, C2-alkynyl, Co cycloalkyl,
Co cycloalkyl-C-alkyl, Co heterocycloalkyl, Co
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl,
Co heteroaryl, and Co. heteroaryl-C-alkyl are each
optionally substituted by one or more independently selected

Rgroups;
or alternatively, R'' and R', taken together with the atoms

to which they are attached, form a heterocycloalkyl or het
eroaryl ring, which is optionally substituted by one or more

R groups;

or alternatively, R'' and R', taken together with the atoms

25
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C. alkyl, Ce haloalkyl, Calkenyl, Ce alkynyl, Co
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl,
Chaloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl,
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl,

gen atom to which they are attached, form a heterocycloalkyl
or heteroaryl ring, which is optionally substituted by one or

more R groups;
each R is independently selected from halo, cyano, nitro,

35

C. alkyl, Chaloalkyl, Chaloalkyl, Calkenyl, C
alkynyl, Calkoxy, Cao cycloalkyl, Cao cycloalkyl-Ca
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-Ca
alkyl, Co-o aryl, Co-o aryl-C-4-alkyl, Coheteroaryl, C-10

heteroaryl-C-alkyl,
40

45

50
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R groups;

each R is independently selected from a protecting group,

to which they are attached, form a heterocycloalkyl or het
eroaryl ring, which is optionally substituted by one or more

Rgroups;
or alternatively, RandR'', taken together with the nitro

Rgroups;
each R' is independently selected from a protecting group,

C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl,
Chaloalkyl, Calkenyl, C- alkynyl, Co cycloalkyl,
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co
heterocycloalkyl-Ca-alkyl, Co aryl, Co aryl-C-alkyl,
Co heteroaryl, and Co. heteroaryl-C-alkyl are each
optionally substituted by one or more independently selected

or alternatively, R'' and R', taken together with the atoms

to which they are attached, form a heterocycloalkyl or het
eroaryl ring, which is optionally substituted by one or more

Rgroups;
each R' is independently selected from a protecting

group, Ce alkyl, Chaloalkyl, Calkenyl, C-alkynyl,
Cao cycloalkyl, Cao cycloalkyl-Ca-alkyl, Coheterocy
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o
aryl-C-alkyl, Co heteroaryl, wherein said C. alkyl,
Chaloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl,
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl,
Co heteroaryl, and Co. heteroaryl-C-alkyl are each
optionally substituted by one or more independently selected

dently selected R groups;

S(=O)R’,

S(=O)R’,

S(=O)NR&R', C(=O)R’, C(=O)NR&R',
OC(=O)R’, OC(=O)NR&R', NR°C(=O)R’,
NR**C(O)OR2, NRC(O)NR3°NR'2, NR'S
(—O).R, NRS(O)NR8R, C( NR)NR8R,
NRC( NR)NR3°R2, OR2, SR2, S(O) OR2,
—C(=O)CR', and - NR'R'': wherein said C, alkyl,

Chaloalkyl, C2-alkenyl, C2-alkynyl, Co alkoxy, Cao
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co
aryl-C-alkyl, Co heteroaryl, and Coheteroaryl-Ca
alkyl are each optionally Substituted by one or more indepen

dently selected R groups;
each R' is independently selected from H, C, alkyl, C.

haloalkyl, C2-alkenyl, C2-alkynyl, Cso cycloalkyl, Cso
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co
heteroaryl, wherein said C. alkyl, Chaloalkyl, Calk
enyl, C2-alkynyl, Cao cycloalkyl, Cao cycloalkyl-Ca
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-Ca
alkyl, Cao aryl, Cao aryl-Ca-alkyl, Co heteroaryl, and
Coheteroaryl-C-alkyl are each optionally Substituted by

one or more independently selected R' groups;

60
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each R” is independently selected from C, alkyl, C.

haloalkyl, Calkenyl, C2-alkynyl, Co cycloalkyl, Co
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero
cycloalkyl-C-alkyl, Co aryl, Co aryl-C-alkyl, Co
heteroaryl, wherein said C. alkyl, Chaloalkyl, C2-alk
enyl, C2-alkynyl, Cao cycloalkyl, Cao cycloalkyl-Ca
alkyl, Co heterocycloalkyl, Co heterocycloalkyl-Ca
alkyl, Cao aryl, Cao aryl-Ca-alkyl, Co heteroaryl, and

US 9.278,959 B2
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Coheteroaryl-C-alkyl are each optionally Substituted by
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or alternatively, RandR, taken together with the atoms

one or more independently selected R' groups;
each Risindependently selected from a protecting group,
C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso
cycloalkyl, Co cycloalkyl-Ca-alkyl, Co heterocy
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl,
Chaloalkyl, Calkenyl, C- alkynyl, Co cycloalkyl,
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl,
Co heteroaryl, and Co heteroaryl-C-alkyl are each
optionally substituted by one or more independently selected

R“groups:
each R" is independently selected from a protecting

group, Co alkyl, Chaloalkyl, C2-alkenyl, C2-alkynyl,
Cao cycloalkyl, Cao cycloalkyl-Ca-alkyl, Coheterocy
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl,
Chaloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl,
Co cycloalkyl-C-alkyl, Co heterocycloalkyl, Co
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl,
Co heteroaryl, and Co. heteroaryl-C-alkyl are each
optionally substituted by one or more independently selected

R“groups:
each R’ is independently selected from a protecting group,

C. alkyl, C- haloalkyl, C2-alkenyl, C2-alkynyl, Cso
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co
aryl-Ca-alkyl, Co heteroaryl, wherein said C. alkyl,
Chaloalkyl, C2-alkenyl, C2-alkynyl, Co cycloalkyl,
Co cycloalkyl-C-alkyl, Co heterocycloalkyl, Co
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl,
Co heteroaryl, and Co. heteroaryl-C-alkyl are each
optionally substituted by one or more independently selected

to which they are attached, form a heterocycloalkyl or het
eroaryl ring, which is optionally substituted by one or more

R“groups:
or alternatively, R° and R', taken together with the nitro

gen atom to which they are attached, form a heterocycloalkyl
or heteroaryl ring, which is optionally substituted by one or
10

15

25
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provided that each hydrogen atom in which is directly
attached to a nitrogen atom, Sulfur atom, or oxygen atom in
any of the aforementioned groups (e.g., heteroaryl, heterocy

protecting group, C-alkyl, Chaloalkyl, C2-alkenyl, C2
alkynyl, Co cycloalkyl, Cao cycloalkyl-Ca-alkyl, Co
heterocycloalkyl, Co heterocycloalkyl-C-alkyl, Co
aryl, Co-oaryl-Ca-alkyl, Coheteroaryl, wherein said C
alkyl, Ce haloalkyl, C- alkenyl, C- alkynyl, Co
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy
cloalkyl, Coheterocycloalkyl-C-alkyl, Co aryl, Co
aryl-Ca-alkyl, Co heteroaryl, and Coheteroaryl-Ca
alkyl are each optionally Substituted by one or more indepen

50

or alternatively, RandR', taken together with the atoms
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dently selected R groups;

to which they are attached, form a heterocycloalkyl or het
eroaryl ring, which is optionally substituted by one or more

R" groups:

or alternatively, RandR', taken together with the atoms

R“groups:

alkylene, Cao cycloalkyl, Cao cycloalkyl-Ca-alkyl, Co
heterocycloalkyl, Co heterocycloalkyl-C-alkyl, Co
aryl, Cao aryl-Ca-alkyl, Co heteroaryl, and Co het
eroaryl-C-alkyl are each optionally substituted by one or
more groups selected from halo, cyano, nitro, Ce alkyl, C.
haloalkyl, Calkenyl, C- alkynyl, Calkoxy, hydroxy,
Calkoxy, Chaloalkoxy, C alkylthio, Calkylsulfi
nyl, Calkylsulfonyl, carbamyl, Calkylcarbamyl, di(C.
alkyl)carbamyl, carboxy, amino, C alkylamino, di-C
alkylamino, Ce alkylcarbonyl, Ce alkoxycarbonyl, C.
alkylcarbonyloxy, Calkylcarbonylamino, Calkylsulfo
nylamino, aminosulfonyl, Ce alkylaminosulfonyl, di(C.
alkyl)aminosulfonyl, aminosulfonylamino, Ce alkylamino
Sulfonylamino, di(C. alkyl)aminosulfonylamino, ami
nocarbonylamino, Ce alkylaminocarbonylamino, di(C.
alkyl)aminocarbonylamino, Co cycloalkyl, Co
cycloalkyl-C-alkyl, Co heterocycloalkyl, Co hetero
cycloalkyl-Ca-alkyl, Coo aryl, Cao aryl-Ca-alkyl, Co
heteroaryland Coheteroaryl-C alkyl; and

each R" is independently selected from Hand C alkyl:

R“groups:
each R', R3 and R' is independently selected from a

to which they are attached, form a heterocycloalkyl or het
eroaryl ring, which is optionally substituted by one or more

C1-alkyl-O-C alkylene, C2-alkenyl, C2-alkynyl, Cso
cycloalkyl, Cao cycloalkyl-Ca-alkyl, C2-1o heterocy
cloalkyl, C2-1o heterocycloalkyl-Ca-alkyl, Co aryl, Co
aryl-C-alkyl, Coheteroaryl, Coheteroaryl-C-alkyl,
hydroxy, Calkoxy, Co haloalkoxy, Co alkylthio. C
alkylsulfinyl, C. alkylsulfonyl, carbamyl, C. alkylcar
bamyl, di(C. alkyl)carbamyl, carboxy, amino, Ce alky
lamino, di-C alkylamino, Ce alkylcarbonyl, Calkoxy
carbonyl, C. alkylcarbonyloxy, Ce alkylcarbonylamino,
Calkylsulfonylamino, aminosulfonyl, Calkylaminosul
fonyl, di(C. alkyl)aminosulfonyl, aminosulfonylamino,
C. alkylaminosulfonylamino, di(C. alkyl)aminosulfony
lamino, aminocarbonylamino, C alkylaminocarbony
lamino, and di(Calkyl)aminocarbonylamino; wherein said
C- alkyl, Ce haloalkyl, C2-alkenyl, C2-alkynyl, C

alkoxy, C. alkyl-NR'—C. alkylene, C. alkyl-O-C-

R“groups:
each R is independently selected from a protecting group,

C. alkyl, Ce haloalkyl, Calkenyl, Ce alkynyl, Co
cycloalkyl, Cso cycloalkyl-Ca-alkyl, C2-o heterocy
cloalkyl, Coheterocycloalkyl-Ca-alkyl, Co aryl, Co-o
aryl-C-alkyl, Co heteroaryl, wherein said C. alkyl,
Chaloalkyl, C2-alkenyl, C2-alkynyl, Cao cycloalkyl,
Cao cycloalkyl-Ca-alkyl, Co heterocycloalkyl, Co
heterocycloalkyl-Ca-alkyl, Cao aryl, Cao aryl-Ca-alkyl,
Co heteroaryl, and Co. heteroaryl-C-alkyl are each
optionally substituted by one or more independently selected

more R groups;
each R is independently selected from halo, cyano, nitro,
C. alkyl, C. haloalkyl, C- alkyl-NR" C. alkylene,

65

cloalkyl, C. alkyl-NR" C. alkylene, hydroxy, car

bamyl, carboxy, amino, Ce alkylamino, Calkylsulfony
lamino, aminosulfonyl, Ce alkylaminosulfonyl,
aminosulfonylamino, Calkylaminosulfonylamino, di(C.
alkyl)aminosulfonylamino, aminocarbonylamino, Calky
laminocarbonylamino, and di(C. alkyl)aminocarbony
lamino) is replaced by a protecting group.
In some embodiments, optionally Substituted means Sub
stituted one or more groups independently selected fromhalo,
cyano, nitro, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl,
cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl,
aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, alkoxy,
haloalkoxy, thio, alkylthio, alkylsulfinyl, alkylsulfonyl, car
bamyl, alkylcarbamyl, carbamyl, carboxy, amino, alky
lamino, di. alkylamino, alkylcarbonyl, alkoxycarbonyl,
H-carbonyloxy, H-carbonylamino, H-Sulfonylamino, amino
Sulfonyl, alkylaminosulfonyl, di(alkyl)aminosulfonyl, ami
nosulfonylamino, alkylaminosulfonylamino, di(alkyl)ami

US 9.278,959 B2
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nosulfonylamino,
aminocarbonylamino,
alkylaminocarbonylamino, dialkyl)aminocarbonylamino,
hydrazine, hydrazines, hydrazides, and semicarbazides;
wherein each group can be further optionally substituted by
one or more groups independently selected from the afore
mentioned groups. In some embodiments, multiple layers of
substitution are permitted.

wherein:

R" is hydrogen or a substituent having a Hammett o, value
of less than Zero; and

In some embodiments, Ar" and Ari do not comprise an iodo
group.

In some embodiments, Ar' is defined as in embodiment (a).
In some embodiments, Aris defined as in embodiment (a).
In some embodiments, Ari is aryl substituted by 1, 2, 3, 4,
or 5 Calkoxy groups.
In some embodiments, Ar’ is aryl substituted by 1, 2, 3, 4,
or 5 methoxy groups.

10

15

In some embodiments, Ar is aryl substituted by 1 or 2C
alkoxy groups.
In some embodiments, Ari is aryl substituted by 1 or 2

alkoxy, substituted or unsubstituted alkyl, substituted or
unsubstituted alkenyl, substituted or unsubstituted alkynyl,
substituted or unsubstituted cycloalkyl, substituted or unsub
stituted heterocycloalkyl, substituted or unsubstituted aryl,

substituted or unsubstituted heteroaryl, and (L)-Z, or one or
more of RandR, RandR', and RandR come together to

form a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl
ring System;
each m, n, and pare independently an integer from 0 to 10;

methoxy groups.

In some embodiments, Ar’ is aryl substituted by 1C
In some embodiments, Ari is aryl substituted by 1 methoxy
group.
In some embodiments, Ar is phenyl substituted by 1,2,3,
4, or 5 Calkoxy groups.
In some embodiments, Ar is phenyl substituted by 1,2,3,
4, or 5 methoxy groups.
In some embodiments, Ar is phenyl substituted by 1 or 2
Calkoxy groups.
In some embodiments, Ar is phenyl substituted by 1 or 2
methoxy groups.
In some embodiments, Ari is phenyl substituted by 1 C.
alkoxy group.
In some embodiments, Ari is phenyl substituted by 1 meth
OXy group.
In some embodiments, Ar is p-methoxyphenyl.
In some embodiments, Ar is 3,4-dimethoxyphenyl.
In some embodiments, Aris Formula (I):

R,R,R,R,R, and Rare independently selected from
aminoalkyl, (CH)N(CH2), —SR, SOR, halo, S.O.R.
(CH), OR, C(=O)NR'R', SONRR, NRSOR,
COOR, NRC(=O)R, NRC(=O)NR', SO.R., (CH),C
(=O)NR'R'', (CH), SONR'R'', (CH)NRSO.R. (CH),
COOR, (CH), NRC(=O)R’, (CH), NRC(=O)NR,

the group consisting of H. CF. OCF, CN, hydroxyl, amino,

each R and Rare independently chosen from H, substi

alkoxy group.

25

tuted or unsubstituted alkyl, substituted or unsubstituted alk
enyl, substituted or unsubstituted alkynyl, substituted or
unsubstituted cycloalkyl, substituted or unsubstituted hetero
cycloalkyl, substituted or unsubstituted aryl, and substituted
or unsubstituted heteroaryl;
L is a linker; and

30

35

Z is a Solid Support.
The aryl rings on the cyclophane moiety can be substituted

or unsubstituted. In some embodiments, R' is selected from
the group consisting of —(C-Co)alkyl, —(C-Co)ha
loalkyl, (C-C)alkenyl, (C-C)alkynyl, —O—(C-C)
alkyl, -C(O)—O—(C-Co.)alkyl, aryl, and heteroaryl. For

example, R' can be -O-(C-Co)alkyl (e.g., OCH). In some
embodiments, R is —O (C-C)alkyl (e.g., OCH). For
example, a compound of Formula (1) can be chosen from:
R1

40

45

50

In some embodiments, one or more of R-R is (L)-Z. L

and Z can be covalently or noncovalently bound to one
another.

In some embodiments, Ar’ is any of the cyclophanes in US
55

60
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2011/0190505, which is incorporated herein by reference in
its entirety.

In some embodiments, Ar' is defined as in embodiment (a):
and Ar is one of the specific embodiments above.
In some embodiments, the present application provides a
compound of Formula I or III as defined herein, wherein Ar"

comprises at least one acid-labile protecting group or acid
sensitive group. In some embodiments, “acid-labile' or
“acid-sensitive” means not stable to or protonated by 1 N
hydrochloric acid.
In some embodiments, the process further comprises Sub
jecting the compound of Formula III to ion-exchange in order
to form a compound of Formula V:

US 9.278,959 B2
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In some embodiments, steps (a) and (b) are carried out in a
single pot.
In some embodiments, the present application provides
compounds of Formula II and processes utilizing compounds
of Formula II (e.g., a process of making a compound of
Formula I, III, V, VI, or VII), wherein the compounds of
Formula II are selected from any of the following:

e
o
A11 NA2
wherein Y is a counterion that is different than X.

In some embodiments, Y is a weakly coordinating anion
(i.e., an anion that coordinates only weakly with iodine). For
example, Y can be the conjugate base of a strong acid, for
example, any anion for which the pKa of the conjugate acid
(H Y) is less than about 1. For example, Y can be triflate,
mesylate, nonaflate, hexaflate, toluene Sulfonate (tosylate),
nitrophenyl Sulfonate (nosylate), bromophenyl Sulfonate
(brosylate), perfluoroalkyl Sulfonate (e.g., perfluoro Co
alkylsulfonate), tetraphenylborate, hexafluorophosphate, tri
fluoroacetate, perfluoroalkylcarboxylate, tetrafluoroborate,
perchlorate, hexafluorostibate, hexachlorostibate, chloride,
bromide, or iodide. In some embodiments, a slightly more
basic leaving group Such as acetate or benzoate may be used.
In some embodiments, the ion-exchange comprises treat
ing the compound of Formula III with an aqueous Solution of
hexafluorophosphate ion, wherein Y is PF -.
In some embodiments, the ion-exchange comprises treat
ing the compound of Formula III with an aqueous Solution of
sodium hexafluorophosphate ion, wherein Y is PF -.
The present application further provides a process of form
ing a compound of Formula III:

10
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2

25

3

30

OP1
III

xe
o
A11 NA2

4
I

2.

35

comprising:
(a) treating a compound of Formula II:
40

Ar—I

II

with more than 2 equivalents of (R'),Si X; and less than 2

equivalents of (1-chloromethyl-4-fluoro-1,4-diazoniabicyclo
2.2.2]octane)bis(tetrafluoroborate) or (1-fluoro-4-methyl-1,
4-diazoniabicyclo[2.2.2]octane)bis(tetrafluoroborate) in the
absence of added acid to form a compound of Formula I:

P2

5

I

P3

45

N

NP4

PIO
50

OP2
6

and

(b) reacting the compound of Formula I with Ar’BFM in

the presence of a catalyst to form a compound of Formula III:

55

wherein:

each X is, independently, a ligand, wherein HX, the con
jugate acid of X, has a pKa of less than or equal to 5:

Ar" is optionally substituted aryl or heteroaryl, wherein Ar"
Ar’ is an optionally substituted aryl or heteroaryl;
each R' is, independently, C. alkyl; and

does not have unprotected protic groups;

60

M is a cation.

In some embodiments, the process utilizes (1-chlorom
ethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane)bis(tet

rafluoroborate); and (R')Si X is (CH)-Si-O(C=O)
CH.

65
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wherein Ar is an optionally substituted aryl or heteroaryl,

wherein Ar does not have unprotected protic groups; and P",
P', P, P', P, and P are each, independently, protecting
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groups. In some embodiments, each X is acetate.
In some embodiments, the present application provides a
compound of Formula I or a process utilizing a compound of
Formula I (e.g., a process of making a compound of Formula 40
III, V, VI, or VII starting from a compound of Formula I; or a
process of making a compound of Formula I), wherein the
compound of Formula I is selected from any of the following:

116

45

109
117

50

OP1
118

110
55

CN
111

60

119

IX

65

OP1

US 9.278,959 B2
39

40

-continued

-continued
128

120

XI

Pl

P2
N

NP2

N

N

121
10

Pl
129

15

122

130

123 25

30

131

124 is

40

132

125
45

133
50

126

55

IX
134
127
60

65

US 9.278,959 B2
42
-continued

-continued
135

p4

144

/

P-N
N

7-CO.P.

?
p11 NU/
IX

10

145

XI

136

p4

N

/

P-N
XI

N

15

7-COP2

N/

p11 N

146
137

C.

COP2
25

147

X

138

30

XI

XI

V

35

148

139

IX2

COP2

40

140
149

COP2
45

OP 1
DX
141 50

COP2
150

XI

N

XI 1
142 55

XI

COP2

-

151
143

60

DX

COP2
65

US 9.278,959 B2
44

43
-continued

-continued
152

157

10

15

158

153

O
25

XI

1N1 O

CN

IX

30

154
159
P

35

n N~
O

40

O

v

XI

1N1O
CN
45

XI

155
160
50

55

XI
CN
60

161
156

IX
65

US 9.278,959 B2
50

s'

-continued
184

190

OP2
10

191

185
15

192

186
25

193

OP2
30

S O

187
35

PIO

IX
194

OP2

N O

40

PIO
45

195

188

50

196

197

US 9.278,959 B2
51
-continued

-continued
198

XI

N

PIO

S

2O7

DX2

X-A

5

PIO

N
Air

O
199
N
10

X-A

PIO

208

PIO

S

IX
15

XI

DOC)O

200

IX

PIO
209

2O

DX2

PIO

Y-A,

2O1

O
25

210

2O2

DX2
30

S

N

PIO

Y-A,

P2

O

XI
203 35
N

o

N

PIO

/

V / N

S

N

211

O

P2

O n
40

XI
PIO

o

N

N

/

N N/

O

XI

204
P

a

45

P2

N

r

OP5

E

OP6

^-nO
p4
P3

XI
205

IX

PIO

C-3O

50

Y.

OP2

IX

212

Pl
P2O

2O6

lu

55

O

213
DX

60

2

Pl
P2O
65

lu

US 9.278,959 B2
53

54

-continued

-continued
214

216

O

P2O lu

5
O

IX
O

215

O
N

10

IX2

IX2

n-1N
S

1.

N

b

15

wherein Ar is an optionally substituted aryl or heteroaryl,

O

wherein Ar does not have unprotected protic groups; and P",
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P', P, P', P, and P are each, independently, protecting
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X is acetate.

In some embodiments, the present application provides a
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compound of Formula III or a process involving a compound
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of Formula III (e.g., a process of making a compound of
Formula III or a process of making a compound of Formula,
VI, or VII):
217

I(X)Ar

218

I(X)Ar

CN

OP1

219

I(X)Ar

220

I(X)Ar

OP1

N1

P2

P3

I(X)Ar

221

222

223

224

P3

n
PIO
OP2

US 9.278,959 B2
71

72
-continued
324

O

O

N-1a

I(X)Ar

es
Pl

wherein Ar is an optionally substituted aryl or heteroaryl,

In some embodiments, the nonpolar Solution of the reac
tion mixture of MW and a compound of Formula V can be
filtered prior to heating. The filtration step can remove any
insoluble material (e.g., insoluble salts) that remain in the

p-methoxyphenyl. In some embodiments, the present appli
cation provides the compound of Formula V corresponding to
compounds 217-324, wherein X is replaced by Y. In some
embodiments, Y is PF - or triflate.
In some embodiments, the present application provides
any of the individual compounds 1-324 disclosed herein. In
Some embodiments, the present application provides any pro
cess described herein utilizing any of compounds 1-324. In
Some embodiments, the present application provides a com
pound of Formula VI or VII, or a salt thereof, derived from
compounds 217-324. In some embodiments, the compound
of Formula VI or VII, or salt thereof, derived from compounds

removed from the filtrate prior to heating (i.e., the residue can
be heated neat).
In further embodiments, the nonpolar solution of the reac
tion mixture of MW and a compound of Formula V can be
filtered prior to heating, the nonpolar solvent can be removed
(e.g., by evaporation), and the heating of the sample can be
performed in a different solvent.

wherein Ar does not have unprotected protic groups; and P",
P', P, P', P, and P are each, independently, protecting
groups; and Art and X are defined above. In some embodi
ments, each X is acetate. In some embodiments, Ar is

217-324 has a fluoro atom (e.g. a 'Fatom) at the position

reaction mixture. In some embodiments, the solvent can be
25

30

In some embodiments, contaminant salts are removed from

35

the solution of the reaction mixture of MW and a compound
of Formula V in the polar or nonpolar solution by chroma
tography. For example, the contaminant salts can be removed
by size exclusion, gel filtration, reverse phase, or other chro
matographic method prior to heating.
Substituted aryls and heteroaryls which are prepared using
the methods described herein can have an W moiety which
includes any moiety in which the pKa of H W (i.e., the
conjugate acid of X) is less than about 12. In some cases, W

corresponding to W or Fin Formulas VI and VII, respectively.
The compounds of Formula III or V can be used to make

fluorinated compounds, including F labeled compounds as
described in in US 2011/0313170 and US 2012/0004417,

which are incorporated herein by reference in its entirety.
For example, the compounds of Formula III or V can be
utilized to prepare compounds of Formula VI:
Ar' W

40

from halide, aryl carboxylate, alkyl carboxylate, phosphate,
phosphonate, phosphonite, azide, thiocyanate, cyanate, phe

noxide, triflate, trifluoroethoxide, thiolates, and stabilized

VI

or a salt thereof, wherein Ar' is as defined above; and W is a
moiety wherein the pKa of the acid H W is less than 12. In
one embodiment, the method includes reacting in a polar
solvent a compound MW, wherein M is a counter ion and W
is as defined in Formula VI and a compound of Formula V:

45

active isotope of fluoride (e.g., 'F).

50

GE)

A11 NA2

55

wherein Ar' and Ari are as defined above. Y is a leaving
group; and

W is as defined above.

60

The polar solvent can then be removed from the reaction
mixture. The remaining mixture can then be combined with a
nonpolar solvent and heated to produce a compound of For
mula VI.

In some embodiments, the method can include heating a
mixture comprising a nonpolar solvent, a compound MW.
and a compound of Formula V.

enolates. For example, W can be fluoride, chloride, bromide,
iodide, trifluoroacetate, benzoate, and acetate. In some
embodiments, X is fluoride. In some embodiments, is a radio

e
I

is a radioactive isotope (e.g., 'F, 'I, I, and compounds
having P and P). In some embodiments, W can be chosen
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Y can be any suitable leaving group. In some embodi
ments, Y is a weakly coordinating anion (i.e., an anion that
coordinates only weakly with iodine). For example, Y can be
the conjugate base of a strong acid, for example, any anion for
which the pKa of the conjugate acid (H Y) is less than about
1. For example, Y can be triflate, mesylate, nonaflate,
hexaflate, toluene Sulfonate (tosylate), nitrophenyl Sulfonate
(nosylate), bromophenyl Sulfonate (brosylate), perfluoro
alkyl Sulfonate (e.g., perfluoro Co alkyl Sulfonate), tet
raphenylborate, hexafluorophosphate, trifluoroacetate, per
fluoroalkylcarboxylate, tetrafluoroborate, perchlorate,
hexafluorostibate, hexachlorostibate, chloride, bromide, or

iodide. In some embodiments, a slightly more basic leaving
group Such as acetate or benzoate may be used.
The counterion M can be any suitable cation for the desired
W. The choice of the source of W. and accordingly M, is
readily within the knowledge of one of ordinary skill in the
art. For example, M can be chosen from an alkali metal,
alkaline earth metal and transition metal salts such as, for
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example, calcium, magnesium, potassium, Sodium and Zinc
salts. Metal cations may also be complexed to cryptands or
crown ethers to enhance their solubility and to labilize the W
moiety. M can also include organic salts made from quater
nized amines derived from, for example, N.N' dibenzylethyl
enediamine, chloroprocaine, choline, diethanolamine, ethyl
enediamine, meglumine (N-methylglucamine) and procaine.
In some embodiments, M can be a lithium, Sodium, potas
sium, or cesium with cryptands or crown ethers, a tetrasub
stituted ammonium cation, or phosphonium cation. When W
is fluoride, the choice of fluoride source is also readily within
the knowledge of one of ordinary skill in the art. A variety of
fluoride sources can be used in the preparation of the fluori
nated aryl and heteroaryl compounds as provided herein,
including but not limited to NaF. KF, CSF, tetrabutylammo
nium fluoride, and tetramethylammonium fluoride. In certain
instances the choice of fluoride source will depend on the
functionality present on the compound of Formula V.
The methods described above can be useful in the prepa
ration of fluorinated aryl and heteroaryl ring systems. For
example, the methods can be used to prepare a compound of

10

15

Formula VII:
Ar

F

VII

or a salt thereof, wherein Ar' is an aryl or heteroaryl ring

25

system. In particular, the methods can be used to prepare
radiolabeled fluorinated aryl and heteroaryl ring systems

(e.g., PET radiotracers). In some embodiments, said F is F.
In some embodiments, the method can include reacting in a
polar solvent a compound MF and a compound of Formula V.
The polar solvent can then be removed from the reaction
mixture. The remaining mixture can then be combined with a
nonpolar solvent and heated to produce a compound of For

are found in Remington's Pharmaceutical Sciences, 17" ed.,

30

Mack Publishing Company, Easton, Pa., 1985, p. 1418 and
Journal of Pharmaceutical Science, 66, 2 (1977), each of
which is incorporated herein by reference in its entirety.
Definitions

mula VII.

In some embodiments, the method can include heating a
mixture comprising a nonpolar solvent, a compound MF, and
a compound of Formula V.
In some embodiments, the nonpolar Solution of the reac
tion mixture of MF and a compound of Formula V can be
filtered prior to heating. The filtration step can remove any
insoluble material (e.g., insoluble salts) that remain in the
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individual subjects so that those individuals with probable
response to the therapy can be identified prior to exposure to
the drug and/or ii) the amount of administered radiopharma
ceutical agent localized in an intended target So that dosage
for the nonradioactive analogous therapeutic agent can be
determined on a patient by patient basis.
In some embodiments, the compounds are provided as
pharmaceutically acceptable salts. As used herein, pharma
ceutically acceptable salts' refers to derivatives of the dis
closed compounds wherein the parent compound is modified
by converting an existing acid or base moiety to its salt form.
Examples of pharmaceutically acceptable salts include, but
are not limited to, mineral or organic acid salts of basic
residues such as amines; alkali or organic salts of acidic
residues such as carboxylic acids; and the like. The pharma
ceutically acceptable salts of the present application include
the conventional non-toxic salts of the parent compound
formed, for example, from non-toxic inorganic or organic
acids. The pharmaceutically acceptable salts of the present
application can be synthesized from the parent compound
which contains a basic or acidic moiety by conventional
chemical methods. Generally, such salts can be prepared by
reacting the free acid or base forms of these compounds with
a stoichiometric amount of the appropriate base or acid in
water or in an organic solvent, or in a mixture of the two:
generally, nonaqueous media like ether, ethyl acetate, etha
nol, isopropanol, or ACN are preferred. Lists of suitable salts

35
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It is appreciated that certain features of the invention,
which are, for clarity, described in the context of separate
embodiments, can also be provided in combination in a single
embodiment. Conversely, various features of the invention
which are, for brevity, described in the context of a single
embodiment, can also be provided separately or in any Suit
able subcombination.

As used herein, the phrase “optionally substituted” means

reaction mixture. In some embodiments, the solvent can be

unsubstituted or substituted. As used herein, the term "sub

removed from the filtrate prior to heating (i.e., the residue can
be heated neat).
In some embodiments, the nonpolar Solution of the reac
tion mixture of MF and a compound of Formula V can be
filtered prior to heating, the nonpolar solvent can be removed
(e.g., by evaporation), and the heating of the sample can be
performed in a different solvent.

stituted” means that a hydrogenatomis removed and replaced
by a substituent. It is to be understood that substitution at a
given atom is limited by Valency. Throughout the definitions,
the term “C” indicates a range which includes the end
points, wherein in and mare integers and indicate the number
of carbons. Examples include C. C., and the like.
The term “n-membered where n is an integer typically
describes the number of ring-forming atoms in a moiety
where the number of ring-forming atoms is n. For example,
piperidinyl is an example of a 6-membered heterocycloalkyl
ring, pyrazolyl is an example of a 5-membered heteroaryl
ring, pyridyl is an example of a 6-membered heteroaryl ring,
and 1.2.3,4-tetrahydro-naphthalene is an example of a
10-membered cycloalkyl group.
As used herein, the term "C., alkyl, employed alone or
in combination with other terms, refers to a saturated hydro
carbon group that may be straight-chain or branched, having
in to m carbons. In some embodiments, the alkyl group con
tains from 1 to 3 carbon atoms. Examples of alkyl moieties
include, but are not limited to, chemical groups such as
methyl, ethyl, n-propyl, and isopropyl.
As used herein, the term "Calkoxy’, employed alone or
in combination with other terms, refers to a group of formula
—O-alkyl, wherein the alkyl group has n to m carbons.
Example alkoxy groups include methoxy, ethoxy, and pro

In some embodiments, contaminant salts are removed from

the nonpolar solution of the reaction mixture of MF and a
compound of Formula V by chromatography. For example,
the contaminant salts can be removed by size exclusion, gel
filtration, reverse phase, or other chromatographic method
prior to heating.
The therapeutic use of compounds of Formula VI or VII
with demonstrated pharmacologic activity in amounts which
are Suitable for modulation of physiologic or pathologic pro
cesses and which, in proportion to the demonstrated clinical
benefits, demonstrate acceptable toxicity. In particular, the

45

50

55
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use of F radiofluorinated molecules of Formula VII claimed

herein as in Vivo medical imaging agents is contemplated for
the diagnosis of disease, the noninvasive demonstration of
physiologic or pathologic processes in Vivo, and for the coor
dinate use of Such in vivo radiopharmaceutical agents with
structurally analogous nonradioactive molecules to deter
mine i) the presence of receptors for the therapeutic agent in

65
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poxy (e.g., n-propoxy and isopropoxy). In some embodi
ments, the alkyl group has 1 to 3 carbon atoms.
As used herein, the term “alkylene', employed alone or in
combination with other terms, refers to a divalent alkyl link
ing group. Examples of alkylene groups include, but are not
limited to, ethan-1,2-diyl, propan-1,3-diyl, propan-1,2-diyl.
butan-1,4-diyl, butan-1,3-diyl, butan-1,2-diyl, 2-methyl-pro
pan-1,3-diyl, and the like.
As used herein, “C., alkenyl refers to an alkyl group
having one or more double carbon-carbon bonds and having
in to m carbons. In some embodiments, the alkenyl moiety
contains 2 to 6 or to 2 to 4 carbon atoms. Example alkenyl
groups include, but are not limited to, ethenyl, n-propenyl,
isopropenyl. n-butenyl, sec-butenyl, and the like.
As used herein, “C., alkynyl refers to an alkyl group
having one or more triple carbon-carbon bonds and having in
to m carbons. Example alkynyl groups include, but are not
limited to, ethynyl, propyn-1-yl, propyn-2-yl, and the like. In
Some embodiments, the alkynyl moiety contains 2 to 6 or 2 to

10

15

4 carbon atoms.

As used herein, the term "C., alkylamino” refers to a
group of formula—NH(alkyl), wherein the alkyl group has n
to m carbonatoms. In some embodiments, the alkyl group has
1 to 6 or 1 to 4 carbon atoms.

to 4 carbon atoms.
25

As used herein, the term "di-C-alkylamino” refers to a
group of formula —N(alkyl), wherein the two alkyl groups
each has, independently, in to m carbon atoms. In some
embodiments, each alkyl group independently has 1 to 6 or 1
to 4 carbon atoms.

30

As used herein, the term "C., alkylsulfonyl refers to a
group of formula—S(O)-alkyl, wherein the alkyl group has
in to m carbon atoms. In some embodiments, the alkyl group
35

has 1 to 6 or 1 to 4 carbon atoms.

As used herein, the term “amino” refers to a group of
formula NH2.
As used herein, the term "Ce alkyl-O-C alkylene’
refers to a group of formula C- alkylene-O-C alkyl.

has 1 to 6 or 1 to 4 carbon atoms.
40
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1 to 4 carbon atoms.

As used herein, the term “aminosulfonylamino” refers to a
group of formula—NHS(O)NH2.
As used herein, the term "C., alkylaminosulfonylamino”
refers to a group of formula —NHS(O)NH(alkyl), wherein
the alkyl group has n to m carbon atoms. In some embodi
ments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "di(C., alkyl)aminosulfony
lamino” refers to a group of formula —NHS(O)N(alkyl).
wherein each alkyl group independently has n to in carbon

As used herein, the term “C, alkylsulfinyl" refers to a
group of formula—S(O)-alkyl, wherein the alkyl group has n
to m carbonatoms. In some embodiments, the alkyl group has
1 to 6 or 1 to 4 carbon atoms.

has 1 to 6 or 1 to 4 carbon atoms.

As used herein, the term “C, alkylcarbonylamino” refers
to a group of formula - NHC(O)-alkyl, wherein the alkyl
group has n to m carbon atoms. In some embodiments, the
alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term “C, alkylsulfonylamino” refers
to a group of formula —NHS(O)-alkyl, wherein the alkyl
group has n to m carbon atoms. In some embodiments, the
alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "aminosulfonyl', employed alone
or in combination with other terms, refers to a group of
formula—S(O)NH2.
As used herein, the term “C, alkylaminosulfonyl refers
to a group of formula —S(O)NH(alkyl), wherein the alkyl
group has n to m carbon atoms. In some embodiments, the
alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "di(C. alkyl)aminosulfonyl”
refers to a group of formula—S(O)N(alkyl), wherein each
alkyl group independently has n to m carbon atoms. In some
embodiments, each alkyl group has, independently, 1 to 6 or

As used herein, the term “C, alkylthio’ refers to a group
of formula—S-alkyl,
wherein the alkyl group has n to m carbon atoms. In some
embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon
atOmS.

As used herein, the term “C, alkoxycarbonyl refers to a
group of formula—C(O)O-alkyl, wherein the alkyl group has
in to m carbon atoms. In some embodiments, the alkyl group

As used herein, the term “C, alkylcarbonyl” refers to a
group of formula—C(O)-alkyl, wherein the alkyl group has
in to m carbon atoms. In some embodiments, the alkyl group
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atoms. In some embodiments, each alkyl group has, indepen
dently, 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "aminocarbonylamino” refers to a
group of formula—NHC(O)NH2.
As used herein, the term "C., alkylaminocarbonylamino'
refers to a group of formula —NHC(O)NH(alkyl), wherein
the alkyl group has n to m carbon atoms. In some embodi
ments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "di(C., alkyl)aminocarbony
lamino” refers to a group of formula - NHC(O)N(alkyl).
wherein each alkyl group independently has n to m carbon
atoms. In some embodiments, each alkyl group has, indepen
dently, 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term “C, alkylcarbamyl” refers to a
group of formula —C(O)—NH(alkyl), wherein the alkyl
group has n to m carbon atoms. In some embodiments, the
alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term “di(C-alkyl)carbamyl refers
to a group of formula C(O)N(alkyl), wherein the two alkyl
groups each has, independently, intom carbonatoms. In some
embodiments, each alkyl group independently has 1 to 6 or 1

60

As used herein, the term "Calkyl-NR" Calkylene'
refers to a group of formula C, alkylene-NR" Calkyl.

As used herein, the term “aryl', employed alone or in
combination with other terms, refers to a monocyclic or poly
cyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocar
bon, such as, but not limited to, phenyl, 1-naphthyl 2-naph
thyl, anthracenyl, phenanthrenyl, and the like. In some
embodiments, aryl is Co aryl. In some embodiments, the
aryl group is a naphthalene ring or phenyl ring. In some
embodiments, the aryl group is phenyl.
As used herein, the term “arylalkyl refers to a group of
formula-alkylene-aryl. In some embodiments, arylalkyl is
Co aryl-C alkyl. In some embodiments, arylalkyl is Co
aryl-C alkyl. In some embodiments, arylalkyl is benzyl.
As used herein, the term “carbamyl refers to a group of
formula C(O)NH2.
As used herein, the term “carbonyl', employed alone or in
combination with other terms, refers to a —C(O)—group.
As used herein, the term "carboxy' refers to a group of
formula –C(O)OH.
As used herein, the term “cycloalkyl, employed alone or
in combination with other terms, refers to a non-aromatic
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cyclic hydrocarbon moiety, which may optionally contain
one or more alkenylene groups as part of the ring structure.
Cycloalkyl groups can include mono- or polycyclic (e.g.,
having 2, 3 or 4 fused, bridged or spiro rings) ring systems.
Also included in the definition of cycloalkyl are moieties that
have one or more aromatic rings fused (i.e., having a bond in

US 9.278,959 B2
77
common with) to the cycloalkyl ring, for example, benzo
derivatives of cyclopentane, cyclopentene, cyclohexane, and
the like. One or more ring-forming carbon atoms of a
cycloalkyl group can be oxidized to form C=O or C=S
linkages. In some embodiments, cycloalkyl is C.
cycloalkyl, which is monocyclic or bicyclic. Examplary
cycloalkyl groups include 1,2,3,4-tetrahydro-naphthalene,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohep
tyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cyclohep
tatrienyl, norbornyl, norpinyl, norcarnyl, adamantyl, and the
like. In some embodiments, the cycloalkyl group is cyclopro
pyl, cyclobutyl, cyclopentyl, or cyclohexyl.
As used herein, the term “cycloalkylalkyl refers to a group
of formula-alkylene cycloalkyl. In some embodiments,
cycloalkylalkyl is C-2 cycloalkyl-C alkyl, wherein the
cycloalkyl portion is monocyclic or bicyclic. In some
embodiments, cycloalkylalkyl is C. cycloalkyl-C alkyl,
wherein the cycloalkyl portion is monocyclic or bicyclic.
As used herein, “C., haloalkoxy' refers to a group of
formula O-haloalkyl having into in carbonatoms. An example
haloalkoxy group is OCF. In some embodiments, the
haloalkoxy group is fluorinated only. In some embodiments,
the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term “halo' refers to a halogen atom
selected from F, Cl, I or Br.

As used herein, the term “Chaloalkyl, employed alone
or in combination with other terms, refers to an alkyl group
having from one halogen atom to 2s +1 halogenatoms which
may be the same or different, where “s' is the number of
carbon atoms in the alkyl group, wherein the alkyl group has
in to m carbon atoms. In some embodiments, the haloalkyl
group is fluorinated only. In some embodiments, the
haloalkyl group is fluoromethyl, difluoromethyl, or trifluo
romethyl. In some embodiments, the haloalkyl group is trif
luoromethyl. In some embodiments, the alkyl group has 1 to

10
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As used herein, the term "heteroarylalkyl refers to a group
of formula alkylene-heteroaryl. In some embodiments, het
eroarylalkyl is Co. heteroaryl-C alkyl, wherein the het
eroaryl portion is monocyclic or bicyclic and has 1, 2, 3, or 4
heteroatom ring members independently selected from nitro
gen, Sulfur and oxygen. In some embodiments, heteroaryla
lkyl is C. heteroaryl-C alkyl, wherein the heteroaryl por
tion is monocyclic orbicyclic and has 1, 2, 3, or 4 heteroatom
ring members independently selected from nitrogen, Sulfur
and oxygen.
As used herein, the term "heterocycloalkyl, employed
alone or in combination with other terms, refers to non

15

25

30

35

aromatic ring system, which may optionally contain one or
more alkenylene or alkynylene groups as part of the ring
structure, and which has at least one heteroatom ring member
independently selected from nitrogen, Sulfur and oxygen.
When the heterocycloalkyl groups contains more than one
heteroatom, the heteroatoms may be the same or different.
Heterocycloalkyl groups can include mono- or polycyclic
(e.g., having 2, 3 or 4 fused, bridged, or spiro rings) ring
systems, including spiro systems. Also included in the defi
nition of heterocycloalkyl are moieties that have one or more
aromatic rings fused (i.e., having a bond in common with) to
the non-aromatic ring, for example, 1,2,3,4-tetrahydro
quinoline and the like. The carbon atoms or heteroatoms in
the ring(s) of the heterocycloalkyl group can be oxidized to
form a C=O, C=S, S=O, or S(=O) group (or other oxi
dized linkage) or a nitrogenatom can be quaternized. In some
embodiments, heterocycloalkyl is 5- to 10-membered C
heterocycloalkyl, which is monocyclic or bicyclic and which
has 1, 2, 3, or 4 heteroatom ring members independently
selected from nitrogen, sulfur and oxygen. Examples of het
erocycloalkyl groups include 1.2.3,4-tetrahydro-quinoline,
aZetidine, azepane, pyrrolidine, piperidine, piperazine, mor
pholine, thiomorpholine, pyran, and a 2-oxo-1,3-oxazolidine

6 or 1 to 4 carbon atoms.

r1ng.

As used herein, the term "heteroaryl', employed alone or in
combination with other terms, refers to a monocyclic or poly
cyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocar
bon moiety, having one or more heteroatom ring members
selected from nitrogen, Sulfur and oxygen. In some embodi
ments, heteroaryl is 5- to 10-membered C. heteroaryl,
which is monocyclic or bicyclic and which has 1, 2, 3, or 4
heteroatom ring members independently selected from nitro
gen, Sulfur and oxygen. The heteroaryl may have one or more
C=O or C=Slinkages. When the heteroaryl group contains
more than one heteroatom ring member, the heteroatoms may
be the same or different. Example heteroaryl groups include,
but are not limited to, pyridine, pyrimidine, pyrazine,
pyridazine, pyrrole, pyrazole, azolyl, oxazole, thiazole, imi
dazole, furan, thiophene, quinoline, isoquinoline, indole,
benzothiophene, benzofuran, benzisoxazole, imidazol-2-b
thiazole, purine, or the like.
A five-membered ring heteroaryl is a heteroaryl with a ring
having five ring atoms wherein one or more (e.g., 1, 2, or 3)
ring atoms are independently selected from N, O, and S.
Exemplary five-membered ring heteroaryls are thienyl, furyl,
pyrrolyl, imidazolyl, thiazolyl, oxazolyl pyrazolyl, isothiaz
olyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1.2.3-thiadiaz
olyl, 1.2.3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl,
1,2,4-oxadiazolyl, 1.3,4-triazolyl, 1.3,4-thiadiazolyl, and
1,3,4-oxadiazolyl.
A six-membered ring heteroaryl is a heteroaryl with a ring
having six ring atoms wherein one or more (e.g., 1, 2, or 3)
ring atoms are independently selected from N, O, and S.
Exemplary six-membered ring heteroaryls are pyridyl,
pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.

As used herein, the term "heterocycloalkylalkyl refers to
a group of formula-alkylene-heterocycloalkyl. In some
embodiments, heterocycloalkylalkyl is Co. heterocy
cloalkyl-C alkyl, wherein the heterocycloalkyl portion is
monocyclic or bicyclic and has 1, 2, 3, or 4 heteroatom ring
members independently selected from nitrogen, Sulfur and
oxygen. In some embodiments, heterocycloalkylalkyl is Co.
heterocycloalkyl-C alkyl, wherein the heterocycloalkyl
portion is monocyclic orbicyclic and has 1, 2, 3, or 4 heteroa
tom ring members independently selected from nitrogen, Sul
fur and oxygen.
The compounds described herein can be asymmetric (e.g.,
having one or more stereocenters). All Stereoisomers, such as

40
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50

55

enantiomers and diastereomers, are intended unless other

wise indicated. Compounds of the present application that
contain asymmetrically Substituted carbon atoms can be iso
lated in optically active or racemic forms. Methods on how to
prepare optically active forms from optically inactive starting
materials are known in the art, Such as by resolution of race
mic mixtures or by Stereoselective synthesis. Many geometric
isomers of olefins, C=N double bonds, and the like can also

60

65

be present in the compounds described herein, and all Such
stable isomers are contemplated in the present application.
Cis and trans geometric isomers of the compounds of the
present application are described and may be isolated as a
mixture of isomers or as separated isomeric forms.
Resolution of racemic mixtures of compounds can be car
ried out by any of numerous methods known in the art. An
example method includes fractional recrystallization using a
chiral resolving acid which is an optically active, salt-forming
organic acid. Suitable resolving agents for fractional recrys
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tallization methods are, for example, optically active acids,
such as the D and L forms of tartaric acid, diacetyltartaric
acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic
acid or the various optically active camphorsulfonic acids
Such as B-camphorsulfonic acid. Other resolving agents Suit
able for fractional crystallization methods include stereoiso
merically pure forms of C.-methylbenzylamine (e.g., S and R
forms, or diastereomerically pure forms), 2-phenylglycinol,
norephedrine, ephedrine, N-methylephedrine, cyclohexyl
ethylamine, 1,2-diaminocyclohexane, and the like.
Resolution of racemic mixtures can also be carried out by
elution on a column packed with an optically active resolving
agent (e.g., dinitrobenzoylphenylglycine). Suitable elution
solvent composition can be determined by one skilled in the

80
for 3-8 h. Acetonitrile was then removed in vacuo and 3x3 mL

dichloromethane were used to extract the remaining mixture.
The combined dichloromethane solutions were washed with

4x6 mL aqueous acetate buffer (NaOAc: HOAc=0.5 M: 0.5
M, pH-5) and dried over sodium sulfate. The dichlo
romethane was removed in vacuo to yield the crude product,
which was dissolved in 3 mL of dichloromethane and dripped
into 150 mL pentane to precipitate the aryliodonium diacetate
products, which were collected by vacuum filtration.
10

Example 1
15

art.

Compounds of the invention also include tautomeric
forms. Tautomeric forms result from the Swapping of a single
bond with an adjacent double bond together with the con
comitant migration of a proton. Tautomeric forms include
prototropic tautomers which are isomeric protonation states
having the same empirical formula and total charge. Example
prototropic tautomers include ketone-enol pairs, amide-imi
dic acid pairs, lactam-lactim pairs, amide-imidic acid pairs,
enamine-imine pairs, and annular forms where a proton can
occupy two or more positions of a heterocyclic system, for
example, 1H- and 3H-imidazole, 1H-, 2H- and 4H-1,2,4triazole, 1H- and 2H-isoindole, and 1H- and 2H-pyrazole.
Tautomeric forms can be in equilibrium or sterically locked
into one form by appropriate Substitution.
Compounds of the invention can also include all isotopes
of atoms occurring in the intermediates or final compounds.
Isotopes include those atoms having the same atomic number
but different mass numbers. For example, isotopes of hydro
gen include tritium and deuterium.
The term, "compound as used herein is meant to include
all stereoisomers, geometric isomers, tautomers, and isotopes
of the structures depicted. Compounds herein identified by
name or structure as one particular tautomeric form are
intended to include other tautomeric forms unless otherwise
specified.
The phrase “pharmaceutically acceptable' is employed
herein to refer to those compounds, materials, compositions,
and/or dosage forms which are, within the scope of Sound
medical judgment, Suitable for use in contact with the tissues
of human beings and animals without excessive toxicity, irri
tation, allergic response, or other problem or complication,

1-(Diacetoxyiodo)-4-methoxybenzene (1a)
AcO-I-OAC

25

OMe

(70%) H NMR (CDCN, 400 MHz, 25° C): & 8.055 (d.
(s, 6H); 'C NMR (CD.CN, 100 MHz, 259 C.) & 177.73,

30

J=9.1 Hz, 2H), 7.053 (d. J=9.1 Hz, 2H), 3.861 (s.3H), 1.905

35

163.73, 138.75, 118.00, 111.97, 56.85, 20.76; HRMS: (HR
FAB) calcd. for CHNOI"M-2OAc+3-NBA 385.9889
found 385.9885. This compound has been prepared previ
ously: Cerioni, G. and G. Uccheddu, “Solution structure of
bis(acetoxy)iodoarenes as observed by 17O NMR spectros
copy, Tetrahedron Lett. 2004, 45,505-507. Characterization
data were consistent with the previous literature.

40
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3-(Diacetoxyiodo)benzonitrile

commensurate with a reasonable benefit/risk ratio.
AcO-I-OAc
50

EXAMPLES

The invention will be described in greater detail by way of
specific examples. The following examples are offered for
illustrative purposes, and are not intended to limit the inven
tion in any manner. Those of skill in the art will readily
recognize a variety of noncritical parameters which can be
changed or modified to yield essentially the same results.
General Procedure for Oxidation of an Iodoarene with

F-TEDA-BF/TMSOAc
Under a dry atmosphere of N, 0.5 mmol of the an aryl
iodide (1-105) was dissolved in 3 mL of dry acetonitrile.
Trimethylsilyl acetate (165 mg, 1.25 mmol) was added to the
solution followed by a solution of F-TEDA-BF (220 mg.
0.65 mmol) in an additional 3 mL of dry acetonitrile. The
reaction mixture was allowed to stand at room temperature

CN
55

H NMR (CD.CN,400 MHz, 25° C): 88.515 (s, 1H, H2),
7.711 (t, J=8.1 Hz, 1H, H5), 1954 (s, 6H, (OCOCH)); 'C
8.406 (d. J–8.1 Hz, 1H, H6), 7.866 (d. J–8.1 Hz, 1H, H4),

60

65

NMR (CDCN, 100 MHz, 25° C) & 178.25 (CO), 140.65
(C6), 139.69 (C2), 136.88 (C5), 132.95 (C4), 121.84 (C3),
115.82 (CN), 109.99 (C1); HRMS (HRFAB): calcd. For
CHNOI M-2Oac+3-NBA+ 380.9736 found
380.9722. (Kazmierczak, P. and L. Skulski, 'A simple, two
step conversion of various iodo arenes to (diacetoxyiodo)
arenes with chromium(VI) oxide as the oxidant'. Synthesis

1998, 1721-1723): 'H NMR (CDC1, 200 MHz) & 7.61-8.39

(4H, m, ArH), 2.02 (6H, s, MeCO).)
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Example 4

2-2-(Di-tert-butoxycarbonyl)aminoethyl-4,5dimethoxy-2-iodobenzene

2-(2S)-2-(Di-tert-butoxycarbonyl)amino-3-meth
oxy-3-oxopropyl-4,5-dimethoxy-2-iodobenzene

Boc

10

MeO

MeO
OMe
15

To a solution of N-iodosuccinamide (NIS) (4.95 g, 22
mmol) in dry acetonitrile (50 mL) was added 2-(3,4dimethoxyphenyl)ethanamine (3.32 mL, 20 mmol) and trif
luoroacetic acid (3.85 mL, 50 mmol) with stirring. The mix
ture was stirred at room temperature in a 250 mL round
bottom flask for two hours. The acetonitrile was removed and

the remaining Solid was taken up in water. The water Solution
was treated with Saturated sodium bisulfite aqueous Solution
until the purple color disappeared. The pH was adjusted to 8
and the aqueous Solution was extracted with dichloromethane
(3x50 mL) The organic layers were combined and dried over
sodium sulfate. The solvent was evaporated to yield 2-(2iodo-4,5-dimethoxyphenyl)ethanamine (4.3 g, 70%). The
crude product was dried under dynamic vacuum overnight
and was sufficiently pure for subsequent steps.
2-(2-iodo-4,5-dimethoxyphenyl)ethanamine (4.3 g) was
dissolved in a dry acetonitrile (30 mL) solution containing
BOC anhydride (4.84g, 22 mmol), 4-dimethylpyridine (195
mg, 1.6 mmol), and triethylamine (3.1 mL, 22 mmol). The
reaction was stirred overnight at room temperature before
being concentrated under reduced pressure. The concentrate
was diluted with 30 mL ethyl acetate and washed with satu
rated NHCl solution, water, and brine. The organic layer was

25

30

35

40

dried over sodium sulfate and concentrated under reduced

pressure. The crude product was purified by column chroma

tography (60 Asilica, 20% ethyl acetate in hexanes, R-03)
before subjected to a second round of BOC protection. The
purified, BOC-protected 2-(2-iodo-4,5-dimethoxyphenyl)

45

ethanamine was dissolved in 30 mL of anacetonitrile solution

containing BOC anhydride (4.36 g. 20 mmol), DMAP (195
mg, 1.6 mmol), and triethylamine (2.78 mL. 20 mmol) and
stirred at room temperature for 20h. The reaction mixture was
concentrated in vacuo, diluted with 30 mL ethyl acetate and
washed with saturated NHCl solution, water, and brine. The
organic layer was dried over sodium sulfate and concentrated
under reduced pressure. The crude product was purified by

50

55

column chromatography (60 A silica, 15% ethyl acetate in
hexanes, R, 0.3) to yield 8.8 g (90%) 2-[2-(di-tert-butoxy
carbonyl)aminoethyl-4,5-dimethoxy-2-iodobenzene. H
NMR (CDCN, 400 MHz, 25° C.): 8 7.25 (s, 1H), 6.72 (s,
1H), 3.77 (t, J=6.60 Hz, 1H), 3.76 (s.3H), 3.74 (s.3H), 2.93

60

product was purified by column chromatography (60 A silica,
20% ethyl acetate in hexanes, R-0.3) before being subjected

to a second round of BOC protection. The product was dis
solved in 40 mL of an acetonitrile solution containing BOC
anhydride (7.17 g. 32.9 mmol), 4-dimethylpyridine (320 mg.
2.63 mmol), triethylamine (4.57 mL, 32.9 mmol) and stirred
at room temperature for 20 h. The reaction mixture was con
centrated in vacuo, diluted with 40 mL ethyl acetate, and
washed with saturated NHCl solution, water, and brine. The
organic layer was dried over Sodium sulfate and concentrated

under reduced pressure. Chromatographic purification (60 A
silica, 15% ethyl acetate in hexanes, R, 0.3) afforded
2-(2S)-2-(Di-tert-butoxycarbonyl)aminol-3-methoxy-3oxopropyl-4,5-dimethoxy-2-iodobenzene (7.63 g, 82%). "H
NMR (CDC1, 400 MHz, 25° C): 8 7.19 (s, 1H), 6.62 (s,
1H), 5.13 (dd, J=11.2 Hz, J-4.3 Hz, 1H), 3.77 (s.3H), 3.76
(s, 3H), 3.74 (s, 3H), 3.44 (dd, J=14.1 Hz, J-4.3 Hz, 1H),

3.30 (dd, J=14.1 Hz, J-11.2 Hz, 1H), 1.36 (s, 18H); 'C

(t, J=6.60 Hz, 1H), 1.41 (s, 18H); C NMR (CDCN, 400
MHz, 25° C): & 170.9, 153.3, 150.6, 149.6, 135.3, 122.9,
114.7,88.9, 82.8, 56.8, 56.4, 47.0, 40. 1, 28.3; HRMS (HREI):
calcd. for CHINOM" 507. 1118 found 507.1122; calcd.
for CHINO IM+Na" 530.1016 found 530.1036.

To a solution of N-iodosuccinamide (8.3g, 37 mmol) in 80
mL of dry acetonitrile were added (S)-3-(3,4-dimethoxyphe
nyl)1-methoxy-1-oxopropan-2-amine hydrochloride (4.63 g,
16.8 mmol) and trifluoroacetic acid (2.7 mL, 37 mmol) with
stirring. The reaction mixture was stirred at room temperature
in a 250 mL round bottom flask protected from light for 2 and
half hours. The acetonitrile was removed and the remaining
solid was taken up into water. The water solution was treated
with saturated sodium bisulfite aqueous solution until the
purple color disappeared. The pH was adjusted to 8 using
saturated sodium bicarbonate Solution. The neutralized aque
ous solution was extracted with dichloromethane (3x50 mL)
The organic layers were combined and dried over sodium
sulfate. The solvent was evaporated to yield (S)-3-(2-Iodo-4,
5-dimethoxyphenyl)-1-methoxy-1-oxopropan-2-amine
(5.17 g., 98%) as a pale yellow oil. The crude product was
dried over dynamic vacuum overnight and was Sufficiently
pure for Subsequent steps.
(5)-3-(2-Iodo-4,5-dimethoxyphenyl)-1-methoxy-1-oxo
propan-2-amine (5.17 g) was dissolved in a dry acetonitrile
(40 mL) solution containing BOC anhydride (7.17 g. 32.9
mmol) and 4-dimethylpyridine (320 mg, 2.63 mmol), triethy
lamine (4.57 mL, 32.9 mmol). The reaction was stirred over
night at room temperature before being concentrated under
reduced pressure. The concentrate was diluted with 40 mL
ethyl acetate and washed with saturated Nff.C1 solution,
water, and brine. The organic layer was dried over Sodium
Sulfate and concentrated under reduced pressure. The crude

NMR (CDC1, 400 MHz, 25° C): & 170.9, 152.3, 149.9,
149.1, 133.1, 122.3, 114.5, 89.2, 83.4, 58.3, 56.6, 56.2, 52.7,

65

40.6, 28.1; HRMS (HRFAB): calcd. for CHINOs
M565.1173 found 565.1168, calcd. for CHINOs
M+H" 566.1251 found 566.1230.
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Example 5
2-(Diacetoxyiodo)-1-2-(di-tert-butoxycarbonyl)
aminoethyl-4,5-dimethoxybenzene (5a)

AcO-I-OAC

Boc
Boc

10

84
4,5-dimethoxy-2-iodobenzene was dissolved in 5 mL dry
acetonitrile and transferred to a 20 mL high density polyeth
ylene vial. Trimethylsilyl acetate (330 mg, 2.5 mmol) and a
solution of F-TEDA-BF (439 mg, 1.30 mmol) in 8 mL dry
acetonitrile were dropwisely added sequentially. The reaction
mixture was allowed to stand at room temperature for 8 h. The
reaction solution was placed in a 100 mL Schlenk flask,
sealed and removed from the glove box. Acetonitrile was
removed by vacuum transfer and the remaining yellow oil
was treated with 3 aliquotes (5 mL) of dichloromethane and
the aliquots were decanted off of the colorless precipitated
salts that remained in the flask. The combined dichlo

MeO
OMe
15

In a Na charged glovebox. 1 mmol (507 mg) of 2-2-(Di
tert-butoxycarbonyl)aminoethyl-4,5-dimethoxy-2-iodo
benzene was dissolved in 5 mL dry acetonitrile and trans
ferred to a 20 mL high density polyethylene vial.
Trimethylsilyl acetate (330 mg, 2.5 mmol) and a solution of
F-TEDA-BF (439 mg, 1.30 mmol) in 8 mL dry acetonitrile
were dropwisely added sequentially. The reaction mixture
was allowed to stand at room temperature for 8 h. The reac
tion solution was placed in a 100 mL Schlenk flask, sealed and
removed from the glove box. Acetonitrile was removed by
vacuum transfer and the remaining yellow oil was treated
with 3 aliquots (5 mL each) of dichloromethane and the
aliquots were decanted off of the colorless precipitated salts
that remained in the flask. The combined dichloromethane

extracts were washed (4x15 mL) with aqueous acetate buffer
(NaOAc: HOAc=0.5 M: 0.5M, pH=5) and dried over sodium
sulfate. The dichloromethane was removed in vacuo to yield
a pale yellow oil. Pentane (8 mL) was added to the oil and
mixture was placed in an ultrasonic bath and Sonicated until
the salt solidified until. The pentane was decanted away and
the remaining light yellow solid was dried under dynamic
vacuum for overnight to yield 381 mg (0.61 mmol. 61%)
2-(Diacetoxyiodo)-1-2-(di-tert-butoxycarbonyl)amino

ethyl-4,5-dimethoxybenzene. H NMR (CDCN, 400 MHz,

romethane extracts were washed (4x15 mL) with aqueous
acetate buffer (NaOAc: HOAc=0.5 M: 0.5 M, pH=5) and
dried over sodium sulfate. The dichloromethane was removed

in vacuo to yield a pale yellow oil. Pentane (8 mL) was added
to the oil and mixture was placed in an ultrasonic bath and
sonicated until the salt solidified until. The pentane was
decanted away and the remaining light yellow solid was dried
under dynamic vacuum for overnight to yield 246 mg (0.36
mmol. 36%) 2-(Diacetoxyiodo)-1-(2S)-2-(di-tert-butoxy
carbonyl)amino-3-methoxy-3-oxopropyl-4,5-dimethoxy

benzene. "H NMR (CDCN, 400 MHz, 25°C.): 8 7.720 (s,
25

1H), 7.011 (s, 1H), 5.236 (dd, J=10.4 Hz, J–3.2 Hz, 1H),
3.864 (s.3H), 3.821 (s.3H), 3.728 (s.3H), 3.676 (dd, J = 14.8
Hz, J–3.2 Hz, 1H), 3.446 (dd, J=14.8 Hz, J-10.4 Hz, 1H),

1898 (s, 6H), 1.352 (s, 9H); C NMR (CDCN, 100 MHz,

30

25° C.) & 171.3, 153.3, 152.7, 149.9, 134.5, 121.6, 114.3,
84.2, 60.8, 57.2, 56.6, 53.3, 39.5, 28.1, 20.5; HRMS: (HR
FAB) calcd. for CHINO" M-2OAc+3-NBA."

703,1358 found 703,1365,

Example 7
35

2-2-(Di-tert-butoxycarbonyl)aminoethyl-4,5dimethoxyphenyl-(4-methoxyphenyl)iodonium
triflate

40

Boc

25°C.): 8 7.732 (s, 1H), 7.047 (s, 1H), 3.882 (s.3H), 3.848 (t,
J=7.6 Hz, 2H), 3.830 (s.3H), 3.120 (t, J=7.6 Hz, 2H), 1.899

Boc

(s, 6H), 1.451 (s.9H); 'C NMR (CDCN, 100 MHz, 25°C.)

& 177.6, 153.8, 153.3, 149.8, 136.5, 1216, 115.9, 113.9, 83.1,

57.1, 56.6, 48.2,39.1, 28.3, 20.6; HRMS: (HRFAB) calcd. for
CHINO" (M-2OAc+3-NBA". 645.1304 found

45

645.1312.
OTf

Example 6

50

2-(Diacetoxyiodo)-1-(2S)-2-(di-tert-butoxycarbo
nyl)amino-3-methoxy-3-oxopropyl-4,5-dimethoxy
benzene (6a)
55

AcO-I-OAC

60

In a N. charged glove box, 381 mg (0.61 mmol) 2-(diac
etoxyiodo)-1-2-(di-tert-butoxycarbonyl)aminoethyl-4,5dimethoxybenzene was dissolved in 2 mL dry acetonitrile. A
saturated solution of potassium (4-methoxylphenyl)trifluo
roborate (130 mg 0.61 mmol) in 5 mL dry acetonitrile was
added to the reaction mixture followed by trimethylsilyl tri
fluoroacetate (113 mg 0.61 mmol) solution in 2.5 mL dry
acetonitrile. Acetonitrile was then removed in vacuo and

MeO

65

In a Na charged glovebox. 1 mmol (565 mg) of 2-(2S)-2(Di-tert-butoxycarbonyl)aminol-3-methoxy-3-oxopropyl

dichloromethane (3x4 mL) were used to extract the remain
ing yellow oil. The combined dichloromethane solutions
were washed (3x10 mL) with aqueous acetate buffer
(NaOAc: HOAc=0.5M: 0.5M, pH=5) and dried over sodium
sulfate. Dichloromethane was removed in vacuo to yield a
pale yellow oil. The oil was dissolved in 2 mL dry acetonitrile
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and poured into a 4 mL aqueous Solution of sodium hexafluo
rophosphate (587 mg, 3.5 mmol) precipitating the diaryliodo
nium hexafluorophosphate salt. The mixture was extracted
with dichloromethane (3x5 mL) and the combined organic
layers were dried over sodium sulfate, and the solvent was
removed under reduced pressure. The crude product was puri

fied by column chromatography (60 A silica, 40% acetone in
hexanes, R, 0.3) to yield 250 mg (2-[2-(Di-tert-butoxycar
bonyl)aminoethyl-4,5-dimethoxyphenyl-(4-methoxyphe
nyl)iodonium hexafluorophosphate (250 mg, 0.33 mmol).
This compound was dissolved in 1 mL acetonitrile/water (9:1
by volume) solution and slowly passed down an Amberlite
IRA-400 ion exchange column (triflate counterion). (The col
umn was prepared for ion exchange by treating the commer
cially obtained Amberlite IRA-400 (Cl) resin with saturated
sodium triflate solution and washing with 10 column volumes
of distilled water.) 2-2-(Di-tert-butoxycarbonyl)amino
ethyl-4,5-dimethoxyphenyl-(4-methoxyphenyl)iodonium
triflate (250 mg, 0.33 mmol) was collected and dried under
dynamic vacuum for 20 h. The salt was dissolved dichlo
romethane (2 mL) and transferred to a 20 mL borosilicate
glass vial. Pentane (18 mL) was carefully layered on top of the
previous dichloromethane Solution. The vial was capped and
the sealed container was shielded from ambient light with
aluminum foil. Colorless needles formed at the solution inter

10

and dried over sodium sulfate. Dichloromethane was
15

25

face; these were collected after 20 h. The needles were sub
30

8.01 (d. J=9.01 Hz, 2H), 7.56 (s, 1H), 7.04 (d.J=9.01 Hz, 2H),
6.95 (s, 1H), 3.84 (s, 3H), 3.83 (s.3H), 3.82 (s.3H), 3.80 (t,

35

J=7.16 Hz, 2H), 3.10 (t, J=7.16 Hz, 2H), 1.44 (s, 18H); 'C

NMR (CDCN, 100 MHz, 25° C.) & 164.3, 1542, 153.8,

151.0, 138.2, 136.6, 120.3, 119.1, 115.2, 107.0, 83.8, 57.3,

2-(2S)-2-(Di-tert-butoxycarbonyl)aminol-3-meth
oxy-3-oxopropyl-4,5-dimethoxyphenyl-(4-meth
oxyphenyl)iodonium triflate (6b)

pressure Minimum amount of ethyl acetate was used to rinse
off the brown color. Remained oil (200 mg, mmol) was dis
solved in a mixture of dichloromethane (2.5 mL) and ethyl
acetate (2.5 mL). This solution was transferred to a 20 mL
borosilicate glass vial. Pentane (15 mL) was carefully layered
on top of the previous solution. Colorless needles formed at
the solution interface; these were collected after 20 h. The

freezer under N. "H NMR (CDCN, 400 MHz, 25° C.): 8

25° C): 8 -79.3 (s, 3F). HRMS: (HREI) calcd. for
C.H.O.NIM-OTf 614.9165. found 614.1627.
Example 8

removed in vacuo to yield a pale yellow oil. Dichloromethane
was removed in vacuo to yield a pale yellow oil. The oil was
dissolved in 3 mL dry acetonitrile and poured into a 3 mL
aqueous solution of Sodium hexafluorophosphate (1 g, 6
mmol) precipitating the diaryliodonium hexafluorophos
phate salt. The mixture was extracted with dichloromethane
(3x6 mL) and the combined organic layers were dried over
sodium sulfate, and the solvent was removed under reduced

jected to a second round of recrystallization using the identi
cal conditions (dichloromethane (2 mL), pentane (18 mL)
layering, 20h in dark) to yield colorless needles of 2-2-(di
tert-butoxycarbonyl)aminoethyl-4,5-dimethoxyphenyl
(4-methoxyphenyl)iodonium triflate (180 mg, 0.24 mmol).
The crystals were dried under vacuum and stored in a -40°C.

56.9, 56.8, 47.4, 38.3, 28.3; F NMR (CDCN, 400 MHz,
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In a N. charged glove box, 492 mg (0.72 mmol) 2-(diac
etoxyiodo)-1-(2S)-2-(di-tert-butoxycarbonyl)amino-3methoxy-3-oxopropyl-4,5-dimethoxybenzene was dis
solved in 2.5 mL dry acetonitrile. A saturated solution of
potassium (4-methoxylphenyl)trifluoroborate (153.4 mg.
0.72 mmol) in 6 mL dry acetonitrile was added to the reaction
mixture followed by trimethylsilyl trifluoroacetate (133.4
mg, 0.72 mmol) solution in 1 mL dry acetonitrile. Acetonitrile
was then removed in vacuo and dichloromethane (3x5 mL)
were used to extract the remaining yellow oil. The combined
dichloromethane solutions were washed (3x12 mL) with
aqueous acetate buffer (NaOAc: HOAc=0.5M: 0.5M, pH=5)

40

needles were subjected to a second round of recrystallization
using the identical conditions (dichloromethane (2.5 mL),
ethyl acetate (2.5 mL), pentane (15 mL) layering, 20 h in
dark) to yield colorless needles of 2-(2S)-2-(Di-tert-bu
toxycarbonyl)amino-3-methoxy-3-oxopropyl-4,5dimethoxyphenyl-(4-methoxyphenyl)iodonium hexafluo
rophosphate (120mg). This compound was dissolved in 1 mL
acetonitrile/water (9:1 by volume) solution and slowly passed
down an Amberlite IRA-400 ion exchange column (triflate
counterion). (The column was prepared for ion exchange by
treating the commercially obtained Amberlite IRA-400 (Cl)
resin with saturated sodim triflate solution and washing with
10 column volumes of distilled water) 2-(2S)-2-(Di-tert
butoxycarbonyl)amino-3-methoxy-3-oxopropyl-4,5dimethoxyphenyl-(4-methoxyphenyl)iodonium

triflate

(120 mg, 0.14 mmol) was collected and dried under dynamic
45

vacuum for 20 h. The salt was dissolved in a mixture of

50

dichloromethane (3 mL) and ethyl acetate (3 mL) This solu
tion was transferred to a 50 mL borosilicate glass Schlenk
tube. Pentane (20 mL) was carefully layered on top of the
previous dichloromethane solution. The tube was capped and
the sealed container was shielded from ambient light with

55

face; these were collected after 48 h to yield colorless needles
of 2-(2S)-2-(Di-tert-butoxycarbonyl)amino-3-methoxy
3-oxopropyl-4,5-dimethoxyphenyl-(4-methoxyphenyl)io
donium triflate (90 mg 0.11 mmol). The crystals were dried

aluminum foil. Colorless needles foilled at the solution inter

under vacuum and stored in a 40° C. freezer under N. "H
60

NMR (CDC1, 400 MHz, 25° C.): 8 7.94 (d. J=8.8 Hz,
H2/H6, 2H), 7.30 (s, H6, 1H), 6.99 (d. J=8.8 Hz, H3/H5',
2H), 6.93 (s, H3, 1H), 5.10 (dd, J–74 Hz, J-7.3 Hz, CH,
1H), 3.85 (s, OCH 3H), 3.84 (s, OCH 3H), 3.76 (s,
–OCH, 3H), 3.74 (s, -COOCH, 3H), 3.62 (dd, J = 14.3
Hz, J-7.3 Hz, —CH, 1H), 3.39 (dd, J=14.3 Hz, J–7.4 Hz,

—CH, 1H), 1.44 (s, Boc, 18H); 'C NMR (CDC1, 400
65

MHz, 25° C): & 1710 (C–O), 163.7 (C4), 153.5 (C–O),
152.7 (C4), 150.8 (C5), 137.5 (C2/C6), 134.4(C2), 118.8
(C6), 118.6 (C3/C5"), 114.6 (C3), 107.6 (C1), 102.7 (C1'),
84.8 (3° C. on Boc), 58.9 (C-C), 57.1 (4-OCH), 56.6
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(5-OCH), 56.4 (4'-OCH), 53.4(COOCH), 39.9 (B-C), 28.2

88
recrystallization by layering in mixed solvent systems
(dichloromethane and pentane or dichloromethane, ethyl
acetate and pentane).

(1° C. on Boc); 'F NMR (CDCN, 400 MHz, 25° C): 8
-79.3 (s, 3F); HRMS (HRFAB): calcd. for CHINO
M-OTf 672.1669, 673. 1703 found.
Example 9
2-(2S)-2-(Di-tert-butoxycarbonyl)aminol-3-meth
oxy-3-oxopropyl-4,5-dimethoxyphenyl)-4-(3.3dimethylbutoxy)phenyl iodonium hexafluorophos
phate

Example 10
Bis(4-methoxyphenyl)iodonium
hexafluorophosphate
10

Recrystallization in a mixture of diethyl ether/dichlo
romethane gave 391 mg of bis(4-methoxyphenyl)iodonium

hexafluorophosphate (80.5%). H NMR (CDCN, 400 MHz,
25° C): 87.973 (d. J=9.1 Hz, 4H, H2/H2/H6/H6), 7.046 (d.
15

J=9.1 Hz, 4 H., H3/H3/H5/H5), 3.833 (s, 6 H, OMe); 'C

NMR (CD.CN, 100 MHz, 25°C.) & 164.61 (C4/C4), 138.55
(C2/C2/C6/C6), 119.42 (C3/C3/C5/C5"), 103.36 (C1/C1'),

57.06 (OMe); 'F NMR (CDCN, 376 MHz, 259 C.)

8 -72.833 (d. 1.JP-F=707.3 Hz, PF ); HRMS (HRFAB):
calcd. for CHOIM-PF)+ 341.0038 found 341.0036.
Example 11
MeO
25

(3,4-Dimethoxyphenyl)(4'-methoxyphenyl)iodonium
hexafluorophosphate

(65%). H NMR (CD.CN, 400 MHz, 25° C): & 7.96 (d.

J=9.1 Hz, 2H), 7.41 (s, 1H), 7.04 (d. J=9.1 Hz, 2H), 6.95 (s,
1H), 5.09 (dd, J =9.3 Hz, J-5.8 Hz, 1H), 4.10 (t, J–7.2 Hz,
2H), 3.82 (s.3H), 3.84 (s.3H), 3.76 (s.3H), 3.75 (s.3H), 3.58
(dd, J=14.7 Hz, J-5.8 Hz, 1H), 3.39 (dd, J=14.7 Hz, J-5.8
HZ, 1H), 1.70 (t, J–7.2 Hz, 2H), 1.38 (s, 18H), 0.97 (s, 9H):

Y,

'C NMR (CDCN, 100 MHz, 25° C) & 1712, 163.8, 153.9,

153.2, 151.1, 138.4, 135.0, 119.7, 115.6, 107.4, 102.4, 85.0,

67.4, 59.3, 57.2, 56.8, 53.5, 42.7, 39.5, 30.4, 29.9, 28.1: 'F

35

NMR (CDCN, 400 MHz, 25°C.): 8 -72.9 (d. J=706.2 Hz,
6F). HRMS: (HREI) calcd. for CHINOPF M-PF+
Nat 742.6703 found 742.2457.
General Procedure for One-Pot Syntheses of Diaryliodonium
Salts from Aryl Iodides
In a Na charged glovebox, 0.5 mmol of an aryl iodide was
dissolved in 3 mL dry acetonitrile. Trimethylsilyl acetate (165
mg, 1.25 mmol) was added to the solution followed by a
solution of F-TEDA-BF (220 mg, 0.65 mmol) in 3 mL dry

40

acetonitrile. The reaction mixture was allowed to stand at

45

e KX
e PF6

Recrystallization with diethyl ether/dichloromethane gave
370 mg (71.7%) of (3,4-dimethoxyphenyl)(4'-methoxyphe

room temperature for 3-8 h. A saturated solution of potassium
(4-methoxylphenyl)trifluoroborate (117.2 mg, 0.55 mmol) in
6 mL dry acetonitrile was added to the reaction mixture.

nyl)iodonium hexafluorophosphate. "H NMR (CDCN, 400

MHz, 25° C): 87.986 (d. J=9.1 Hz, 2 H, H2/H6"), 7.647 (dd,
J1=8.9 Hz, J2–2.2 Hz, 1 H, H6), 7.558 (d. J=2.2 Hz, 1 H, H2),
7.049 (d. J=9.1 Hz, 2 H., H3/H5'), 7.022 (d. J=8.9 HZ, 1 H,
H5), 1543.845 (s.3 H, 3-OMe), 3.843 (s.3 H, 4'-OMe), 3.834

(s, 3 H, 4-OMe); 'C NMR (CDCN, 100 MHz, 25° C.) &
164.58 (C4), 154.62 (C4), 152.50 (C3), 138.49 (C2/C6'),
130.65 (C6), 119.38 (C2), 119.13 (C3/C5'), 115.52 (C5),
103.37 (C1), 102.64 (C1'), 57.49 (3-OMe), 57.14 (4'-OMe),

57.05 (4-OMe); F NMR (CDCN, 376 MHz, 25° C.)

Acetonitrile was then removed in vacuo and 3x3 mL dichlo

romethane were used to extract the remaining yellow oil. The
combined dichloromethane solutions were washed (4x6 mL)
with aqueous acetate buffer (NaOAc: HOAc=0.5 M: 0.5 M,
pH-5) and dried over sodium sulfate. The dichloromethane
was removed in vacuo to yield the crude product, which was
purified by silica gel chromatography and/or crystallization.
After recrystallization, the obtained acetate salts were subject
to ion exchange to either the hexafluorophosphate or triflate
salts. Typically, the acetate salt was dissolved in minimum
amount of acetonitrile/water (9:1 by volume) solution and
slowly passed down an Amberlite IRA-400 ion exchange
column (triflate or hexafluorophosphates counterion). (The
column was prepared for ion exchange by treating the com
mercially obtained Amberlite IRA-400 (Cl) resin with satu
rated sodium triflate or sodium hexafluorophosphate solution
and washing with 10 column volumes of distilled water.) The
triflate or hexafluorophosphates salts were collected and
dried under dynamic vacuum for 20 h and submitted to

/

30

50

55

60

65

8 -72.786 (d. 1.JP-F=705.8 Hz, PF ); HRMS (HRFAB):
calcd. for CHOIM-PF)+371.0144 found 371.0156.
Example 12
(2-Methoxyphenyl)(4'-methoxyphenyl)iodonium
hexafluorophosphate
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mixture until the vial was full. The vial was sealed and pro
tected from the light. After 3 days, the crystallized product
was collected by vacuum filtration to give (2-methoxy-5-(2(4-methoxyphenyl)propan-2-yl)phenyl)(4-methoxyphenyl)
iodonium hexafluorophosphate as colorless crystalline

94
ethylamine dicarbonate)(4-(3.3-dimethylbutoxyphenyl)io
donium hexafluorophosphate as a white amorphous Solid;

yield 0.49 g (65.2%) 'H NMR (CDCN)400 MHz & 0.968 (s,
9H), a 1.440 (s, 18H), & 1.692 (t, J=7.2 Hz, 2H), & 3.100 (t,
J=7.2 Hz, 2H), a 3.795 (t, J–7.2 Hz, 2H), & 3.815 (s, 3H), 8
3.843 (s, 3H), a 4.093 (t, J–7.2 Hz, 2H), & 6.954 (s, 1H), 8
7.024 (d. J=8.4 Hz, 2H), & 7.544 (s, 1H). & 7.990 (d. J=8.4 Hz,

needles; yield 0.30 g (52%). "H NMR (CDCN)400 MHz &
1.619 (s, 6H), 83.762 (s.3H), 83.854 (s.3H), 83.920 (s.3H),
& 6.798 (d. J=8.2 Hz, 2H), & 6.982 (d. J=8.4 Hz, 2H), & 7.095
(d. J–8.4 Hz, 2H), 8 7.112 (d. J=8.4 Hz, 1H), 87.471 (dd.
J=8.2 Hz, J-2.8 Hz, 1H), 8 7.620 (d. J=2.8 Hz, 1H), 87.897
(d. J=8.4 Hz, 2H).
Example 21
(N,N-di-(t-butoxycarbonyl)-2-((4.5-dimethoxyphen
ethylamine dicarbonate)(4-methoxyphenyl)iodonium
hexafluorophosphate

MeO

2H). C NMR (CDCN) 100 MHz & 28.60, 30.23, 30.71,

10

38.63, 43.05, 47.72, 57.13, 57.63, 67.61, 84.10, 103.07,
107.39, 115.45, 119.83, 120.68, 136.84, 138.45, 151.16,

154.01, 154.39, 163.90. F NMR (CD.CN) 376 MHz
8-79.36.

Example 23

15

(3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-meth
oxyphenyl)iodonium hexafluorophosphate

N(Boc)

N
MeO

On

2

I GE

e PF

25

ePF

N

Šs

"6

o1
The pasty solid was dissolved in 3 mL dichloromethane
and 7 mL of hexanes was layered on top, and this mixture was
sealed in a vial protected from light. After the solid had
crystallized, it was collected by vacuum filtration to afford
(N,N-di-(t-butoxycarbonyl)-2-(4,5-dimethoxyphethylamine
dicarbonate)(4-methoxyphenyl)iodonium hexafluorophos

phate as a white amorphous solid; yield 0.49 g (65.2%) 'H

30

35

The crude filtered product was dissolved in CHCl to
remove it from the filter and the solvent was evaporated. The
colorless solid was recrystallized from CHCl2/heptanes to

40

(300 MHz, CDCN) 8–8.63 (d. 1 H, J=4.8 Hz), 8.49 (d. 1 H,
J=1.2 Hz), 8.40 (s, 1 H), 8.21 (d. 1 H, J=0.8 Hz), 8.01 (d. 2 H,
J=9.2 Hz), 7.90 (t, 1 H, J=7.6 Hz), 7.68 (d. 1 H, J=7.6 Hz),
7.48 (t, 1 H, J=6.2 Hz), 7.10 (d. 2 H, J=9.2 Hz), 3.86 (s.3 H):

NMR (CDCN)400 MHz & 144 (s, 18H), & 3.10 (t, J=7.16
Hz, 2H), & 3.80 (t, J=7.16 Hz, 2H), & 3.82 (s.3H), & 3.83 (s,
3H), 83.84 (s.3H), & 6.95 (s, 1H), & 7.04 (d. J=9.01 Hz, 2H),

& 7.56 (s, 1H), 88.01 (d. J=9.01 Hz, 2H). CNMR (CDCN)
100 MHz & 28.3, 38.3, 47.4, 56.8, 56.9, 57.3, 83.8, 107.0,
115.2, 119.1, 120.3, 136.6, 138.2, 1510, 153.8, 154.2, 164.3.

F NMR (CDCN)400 MHz 8 -72.9 (d. J–707.0 Hz, 6F).

45

Example 22
(N,N-di-(t-butoxycarbonyl)-2-(4,5-dimethoxyphen
ethylaminedicarbonate)(4-(3,3-dimethylbutoxyphe
nyl))iodonium hexafluorophosphate

O

give a colorless, crystalline solid. (14.6 mg, 50%). "H NMR

'C NMR (75 MHz, CDCN) &=150.51, 14136, 139.12,
138.22, 137.92, 136.81,
127.89, 124.35, 118.44, 117.30, 115.64, 55.84; F NMR

HRMS: (HREI) calcd. for C.H.O.NIPF M-PF+Na"
614.9165. found.

CN

50

N(Boc)
55

(282 MHz, CDCN):-72.96 (d. 6F, J-705 Hz); HR-FABMS:
(M-PF)+ 437.014.9 m/z (calcd for CHINO, 437.0145).
Example 24
(3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)
(4-methoxyphenyl)iodonium hexafluorophosphate

N

On

2
N

ePF

Šs

o

60

The pasty solid was recrystallized by dissolving the solid in
3 mL dichloromethane and layering 7 mL of hexanes and
sealing the contents in a vial, protected from light. After the
solid had crystallized, it was collected by vacuum filtration to
afford (N.N-di-(t-butoxycarbonyl)-2-(4,5-dimethoxyphen

CN
65

The crude product was recrystallized from CH2Cl2/hep

tanes to give a colorless, crystalline solid (12.5 mg, 50%). "H
NMR (400 MHz, CDCN): 8–8.47 (s, 1 H), 8.39 (s, 1 H), 8.20
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(s, 1 H), 8.07 (d. 2 H, J=8.1 Hz), 7.72 (t, 1 H, J=8.0 Hz), 7.44
(d. 1 H, J=8.0 Hz), 7.29 (d. 1 H, J=8.0 Hz),

96
In a Na charged glovebox, (S)-methyl 2-bis-(tert-butoxy
carbonyl)amino)-3-(4-iodophenyl)propanoate)(bis-acetyly

NMR (100 MHz, CDCN): 8=163.82, 159.59, 14136,

dry, distilled acetonitrile. In a separate flask, potassium
(4-methoxyphenyl)trifluoroborate (0.34g, 1.6 mmol) was
dissolved in 13 mL of dry, distilled acetonitrile and was
subsequently added to the hypervalent iodine solution. Next,
trimethylsilyl trifluoroacetate (0.29 g, 1.6 mmol) was added
dropwise to the reaction vial while stirring. After 10 minutes
at room temperature the solvent was removed in vacuo to
yield an oil. The oil was dissolved in 20 mL of dichlo
romethane and the organic layer was washed with aqueous
acetate buffer (3x12 mL) (NaOAc: HOAc: 0.5M:0.5M; pH
5). The dichloromethane layer was removed in vacuo to yield
a light yellow solid. The solid was redissolved in 4 mL of dry
acetonitrile and an aqueous solution of sodium hexafluoro
phosphate (1.0 g in 4 mL deionized water) was added to the

oxy)-v-iodane (1.0g, 1.6 mmol) was dissolved in 5.6 mL of

7.10 (d. 2 H, J=9.2 Hz), 3.86 (s, 3 H), 2.52 (s, 3 H). 'C

140.57, 139.16, 138.29, 137.89, 137.10, 126.78, 125.09,
124.06, 118.49, 115.66, 112.93, 101.28,93.33, 82.99, 55.85,

23.46; F (376 MHz, CDCN) &=-72.79 (d. 6F, 703.1 Hz);
HR-FAB MS: (M-PF)* 451.0299 m/z (calcd for
CHINO, 451.03).
Example 25
4-(Diacetoxyiodo)-1-(2S)-2-(di-tert-butoxycarbo
nyl)amino-3-methoxy-3-oxopropylbenzene

10

15

O

reaction flask and the solution was stirred for 3 minutes. The

formed residue was extracted with dichloromethane (3x20
mL), the organic layers combined and over Sodium sulfate,
and removal of the solvent in vacuo gave a white solid. The

N(Boc)

AcO- I

white solid was redissolved in 3 mL of an acetonitrile/water
OAc

In a N. charged glove box, (5)-methyl 2-bis-(tert-butoxy
carbonyl)amino)-3-(4-iodophenyl)propanoate (6.4 g, 12.6
mmol) was dissolved in 63 mL of dry, distilled acetonitrile in
a plastic container. To the same container was then added
trimethylsilyl acetate (4.2 g, 31.4 mmol) and the reaction
mixture was stirred. In a separate plastic flask, SelectFluor R
was dissolved in 103 mL of dry, distilled acetonitrile and the
Selectfluorr mixture was added dropwise to the phenylala
nine/trimethylsilyl acetate mixture while stirring, and the
solution was allowed to stir for 8 hours. After 8 hours, the

acetonitrile was removed in vacuo to yield a white solid. The
solid was washed with dichloromethane (3x50 mL) and the
organic fractions were combined. The organic layer was
washed with aqueous acetate buffer (4x40 mL) (NaOAc:
HOAc: 0.5M:0.5M; pH 5), and the organic layer was dried
over sodium sulfate. The dichloromethane was removed in

vacuo to give a yellow oil, which was treated with 40 mL of
pentanes and Subjected to an ultrasonic water bath until the
salt solidified. The pentane was decanted and the white solid
was placed under high dynamic vacuum for 5 hours. The
white solid was then carried forward to the next step without

25

(90:10) solution and passed through an IRA-400 resin previ
ously loaded with trifluoromethanesulfonate anion with an
additional 25 mL of acetonitrile/water (90:10). The solvent

was removed in vacuo to give a colorless oil. "H NMR
30

(CDCN)400 MHz & 121 (s, 18H), & 3.21 (dd, J = 11.3 Hz,
J–14.0 Hz, 1H), & 3.42 (dd, J=11.3 Hz, J-14.0 Hz, 1H), 8
3.69 (s.3H), 63.83 (s.3H), 65.16 (dd, J-49 Hz, J-10.9 Hz,
1H), & 7.05 (d. J=8.4 Hz, 2H), 8 7.33 (d. J=8.4 Hz, 2H), 87.96
(d. J=8.4 Hz, 2H), 88.02 (d. J=8.4 Hz, 2H).
What is claimed is:

35

40

1. A process for making a compound of Formula I:

comprising:
treating a compound of Formula II:
Ar—I

II

18H), 8 1.93 (s, 6H), 83.29 (dd, J=11.3 Hz, J-140 Hz, 1H),
83.48 (dd, J=11.3 Hz, J-140 Hz, 1H),83.75 (s.3H),85.25
(dd, J=11.3 Hz, J-14.0 Hz, 1H), 87.38 (d. J–8.4 Hz, 2H), 8
8.07 (d. J=8.4 Hz, 2H).
Example 26

50

with (A) a tetravalent silicon moiety having at least one X
group bound to Si, wherein each X is, independently, a
ligand that is a conjugate base of an acid HX, wherein
HX has a pKa of less than or equal to 12; and is selected
from the group consisting of halide, aryl carboxylate,
alkyl carboxylate, phosphate, phosphonate, phospho
nite, azide, thiocyanate, cyanate, phenoxide, triflate, thi

4-((2S)-2-(di-tert-butoxycarbonyl)aminol-3-meth
oxy-3-oxopropylphenyl)-4-(3.3-dimethylbutoxy)
phenyl iodonium triflate

55

(B) (1-chloromethyl-4-fluoro-1,4-diazoniabicyclo2.2.2
octane) bis(tetrafluoroborate), (1-fluoro -4-methyl-1,4diazoniabicyclo[2.2.2]octane) bis(tetrafluoroborate), or
an optionally substituted N-fluoropyridinium tetrafluo

45

other purification. "H NMR (CDCN) 400 MHz & 1.40 (s,

olates, and Stabilized enolates; and

roborate;
wherein:

Ar" is selected from the group consisting of:
60

N(Boc)

GOTf

65
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wherein Ar is an optionally substituted aryl or heteroaryl,
wherein Ardoes not have unprotected protic groups; and

P', P, P, P', P, and P are each, independently, pro

tecting groups.
2. The process of claim 1, wherein the process is carried out
in the absence of added acid.
25

104

30

105
35

mula II.

O

P2O

40

45

O

7. The process of claim 1, wherein the process utilizes less
than 1.5 equivalents of (1-chloromethyl-4-fluoro-1,4-diazo
niabicyclo[2.2.2]octane) bis(tetrafluoroborate), (1-fluoro-4methyl-1,4-diazoniabicyclo[2.2.2]octane) bis(tetrafluorobo
rate), or optionally substituted N -fluoropyridinium
tetrafluoroborate for 1 equivalent of the compound of For
mula II.
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P2O
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8. The process of claim 1, wherein each X is, indepen
dently, a ligand that is a conjugate base of an acid HX.
wherein HX has a pKa of less than or equal to 5.
9. The process of claim 1, wherein each X is O(C=O)CH.
10. The process of claim 1, wherein the tetravalent silicon

moiety is (R'),Si X, wherein each R' is, independently,
11. The process of claim 10, wherein each R" is methyl.
12. The process of claim 10, wherein (R'),Si X is
(CH)Si X.
13. The process of claim 10, wherein (R'),Si X is

C. alkyl or aryl.

107
I

55

O

3. The process of claim 1, wherein the process utilizes
(1-chloromethyl-4-fluoro -1,4-diazoniabicyclo[2.2.2]oc
tane) bis(tetrafluoroborate).
4. The process of claim 1, wherein the process utilizes
(1-fluoro-4-methyl-1,4-diazoniabicyclo 2.2.2]octane) bis
(tetrafluoroborate).
5. The process of claim 1, wherein the process utilizes
N-fluoro-2,3,4,5,6-pentachloropyridinium tetrafluoroborate.
6. The process of claim 1, wherein the process utilizes less
than 2 equivalents of (1-chloromethyl-4-fluoro-1,4-diazoni
abicyclo[2.2.2]octane) bis(tetrafluoroborate), (1-fluoro-4methyl-1,4-diazoniabicyclo[2.2.2]octane) bis(tetrafluorobo
rate), or optionally substituted N -fluoropyridinium
tetrafluoroborate for 1 equivalent of the compound of For

and
60

(CH),Si-O(C=O)CH.
14. The process of claim 1, wherein the process utilizes 2
equivalents or more of the tetravalent silicon moiety for 1
equivalent of the compound of Formula II.
15. The process of claim 1, wherein the process utilizes 2.5
equivalents to 3 equivalents of the tetravalent silicon moiety
for 1 equivalent of the compound of Formula II.
16. The process of claim 15, wherein the tetravalent silicon

moiety is (R'),Si X, wherein each R' is, independently,

65

C. alkyl or aryl.
17. The process of claim 1, wherein the processes com
prises treating a compound of Formula II with (CH)-Si-O

US 9.278,959 B2
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(C—)CH; and (1-chloromethyl-4-fluoro-1,4-diazoniabicy
clo2.2.2]octane) bis(tetrafluoroborate).
18. The process of claim 1, wherein the processes com
prises treating a compound of Formula II with 2.5 equivalents
to 3 equivalents of (CH),Si-O(C=O)CH; and less than
1.5 equivalents of (1-chloromethyl-4-fluoro-1,4-diazoniabi
cyclo[2.2.2]octane) bis(tetrafluoroborate).
19. A process for making a compound of Formula III:
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wherein Ar’ is an optionally substituted aryl or heteroaryl,
the process comprising:
treating a compound of Formula II:
Ar—I

15

II

with (A) a tetravalent silicon moiety having at least one X
group bound to Si, wherein each X is, independently, a
ligand that is a conjugate base of an acid HX, wherein
HX has a pKa of less than or equal to 12; and is selected
from the group consisting of halide, aryl carboxylate,
alkyl carboxylate, phosphate, phosphonate, phospho
nite, azide, thiocyanate, cyanate, phenoxide, triflate, thi
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olates, and Stabilized enolates; and

(B) (1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2
octane) bis(tetrafluoroborate), (1-fluoro-4-methyl-1,4diazoniabicyclo[2.2.2]octane) bis(tetrafluoroborate), or
an optionally substituted N-fluoropyridinium tetrafluo

30

roborate;
wherein:

Ar' is selected from the group consisting of:
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treating a compound of Formula II:

-continued
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Ar—I
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with (A) a tetravalent silicon moiety having at least one X
group bound to Si, wherein each X is, independently, a
ligand that is a conjugate base of an acid HX, wherein
HX has a pKa of less than or equal to 12; and is selected
from the group consisting of halide, aryl carboxylate,
alkyl carboxylate, phosphate, phosphonate, phospho
nite, azide, thiocyanate, cyanate, phenoxide, triflate, thi

15

(B) (1-chloromethyl-4-fluoro-1,4-diazoniabicyclo2.2.2
octane) bis(tetrafluoroborate), (1-fluoro-4-methyl-1,4diazoniabicyclo 2.2.2octane) bis(tetrafluoroborate), or
an optionally substituted N-fluoropyridinium tetrafluo

O

N-1a
S

1.

I,

olates, and Stabilized enolates; and

N

Pl

II

roborate;

wherein Ar is an optionally substituted aryl or heteroaryl,
wherein Ardoes not have unprotected protic groups; and

wherein:

Ar' is selected from the group consisting of:

P', P, P, P', P, and P are each, independently, pro

tecting groups;
to prepare a compound of Formula I:

25

2

and

converting the compound of Formula I into a compound of
Formula III.
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20. The process of claim 19, wherein said converting com
prises reacting the compound of Formula I with a compound
of Formula IV:

3
35

wherein M' is aborate, stannane, silane, or zinc moiety.
21. The process of claim 20, wherein M' is Sn(R),
Si(R), B(OR), or BCX),M; wherein:
each R is, independently, C, alkyl;
each R' is, independently, Ce alkyl,
each R is, independently, OH or C. alkoxy; or two R.
groups, taken together with the oxygen atoms to which
they are attached and the boron atom to which the oxy
gen atoms are attached, form a 5- to 6-membered het
erocyclic ring, which is optionally substituted with 1, 2,
3, or 4C alkyl groups;

OP1,
40

4
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45

each X is, independently, halo; and

N1

M is a counterion.

22. The process of claim 21, wherein the compound of

50

5

Formula IV is ArBFM.
23. The process of claim 21, wherein the compound of
Formula IV is ArBFK.

24. The process of claim 22, wherein the process is carried
out in the presence of a catalyst.
25. The process of claim 24, wherein the catalyst is trim
ethylsilyl trifluoroacetate.
26. A process for making a compound of Formula V:
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wherein Y is a counterion that is different than X, the

process comprising:
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to prepare a compound of Formula I:
108
I

5
O

-IX):

O

N-1N

I,

converting the compound of Formula I into a compound of
Formula III; and

Subjecting the compound of Formula III to ion-exchange in
S

Pl

wherein Aris an optionally substituted aryl or heteroaryl,
wherein Ardoes not have unprotected protic groups; and

P', P, P, P', P, and P are each, independently, protecting groups;

15

order to form a compound of Formula V.
27. The process of claim 26, wherein Y is PF or triflate.

28. The process of claim 26, wherein said ion-exchange
comprises treating the compound of Formula III with an
aqueous solution of hexaflurophosphate ion, wherein Y is

PF.
:k

k

<

k

